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Abstract 
Bifidobacteria and Lactobacilli are purportedly beneficial to human health and are called 
probiotics which are live microorganisms, when administered in adequate amounts conferring a 
health benefit on the host. It is believed that the maximum probiotics effect can be achieved if 
the organisms adhere to intestinal mucosal cells. Probiotics, perhaps in combination with 
prebiotics, may become an important means of preventing and treating disease. In fact, several 
types of diarrhea have been successfully treated with probiotics. The mechanisms behind 
favorable clinical outcome are still largely unknown, however, the potential benefits of probiotic 
therapy promise to be almost limitless. Organic acids offer therapeutic/health benefits, such as 
increasing of pancreatic secretion. 
Prebiotics, such as oligosaccharides and polysaccharides, are defined as nondigestible food 
ingredients that beneficially affect host health by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the colon. Shiitake mushroom (Lentinus 
edodes) is an edible and medicinal mushroom popular in Japan, with a prominent activity in very 
small dosages. Shiitake mushroom extract contains many of oligosaccharides and 
polysaccharides for this reason it is considered as prebiotics. Lactobacillus and bifidobacteria are 
thought to stimulate the immune system, produce B vitamins, inhibit pathogen growth, reduce 
blood ammonia and blood cholesterol levels, and help to restore the normal flora after antibiotic 
therapy. The probiotics are encouraged to grow by oligosaccharides and polysaccharides. 
The overall goal of this project is to develop a new technique that could be applied in the food 
industry to ensure food-grade probiotics that extend the viability longer, express α-galactosidase/ 
β-galactosidase, and overall to enhance the quality of dairy products. Specific objectives to be 
accomplished are as follows: 1) to investigate the effect of mushroom extract on growth of 
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bifidobacteria and lactobacillus in vitro; 2) to determine the effect of shiitake mushroom extract 
on the pH, titratable acidity, viability and α-galactosidase/ β-galactosidase of probiotics in milk 
during refrigerated storage; 3) to study the impact of mushroom extract on viability and α-
galactosidase/β-galactosidase activities of probiotics in yogurt products during refrigerated 
storage. 
The proposed research will build and extend our knowledge to develop food-grade probiotics, 
which can extend probiotics viability, produce higher α-galactosidase/β-galactosidase activity 
and enhance the quality of the dairy products. Information obtained from this study will be 
valuable in developing strategies for the industrial application of this food grade bacteria and 
enzymes in dairy products. 
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CHAPTER 1 
General Introduction 
Human intestinal tract plays a vital role in overall health, not only allowing life-
supporting nutrients to be absorbed, but also providing the first line of defense as a physical and 
immune barrier to food antigens or  microorganisms that human may ingest. Within this 
environment is a highly active society of approximately 500 different species of bacteria that can 
have both harmful and beneficial effects on your health (Arunachalam, 1999; Isolauri, 2001). 
While it is imperative for one‟s overall health that the beneficial bacteria dominate, many factors 
can lead to an imbalance in favor of harmful bacteria, such as a poor diet, antibiotics, and 
contaminated food and water (Sulivan, 2001). Adding probiotics to food ingredients resulted in 
lowered blood cholesterol, and lowered blood pressure (Anderson & Gilliland, 1999; Seppo,  
Jauhiainen, Poussa, & Korpela, 2003). 
Humanity is facing a progressive increase in immune-mediated, gut related health 
problems. Such as allergies and autoimmune and inflammatory diseases, and genetic factors are 
unlikely explanation for these rapid increases in diseases incidence (Sgouras et al., 2004; 
O‟Toole & Cooney, 2008). Two environmental factors that related to the modern lifestyle in 
most world societies are hygiene and nutrition. There has been a decline in the incidence of 
microbial stimulation by infectious diseases as a result of improved hygiene, vaccination, and 
antimicrobial medicine. The development of probiotics, functional foods aims to provide a 
microbial stimulus to the host immune system by means of beneficial live microorganism 
cultures that are characteristic of healthy human gut microflora (Ibrahim, Hassan, Salameh, & 
Shahbazi, 2005) Therefore, the need from health conscious consumers has lead to be a high 
priority of various functional foods. Nowadays food science and technology has shown 
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development of prebiotics, which is dramatically improving the human gut microflora (Aida, 
Shuhaimi, Yazid, & Maaruf, 2009). 
 Probiotics bacteria were shown as gut defense lines. Therefore, we have to support our 
defense lines by consuming more of lactobacillus and bifidobacteria showing characteristics of 
high adherence to human gut. A proliferation of unhealthy bacteria can damage human intestinal 
lining and lead to the production of carcinogenic compounds and intestinal symptoms such as 
bloating, gas, diarrhea, and abdominal pain (Isolauri, Sutas, Kankaanpaa, Arvilommi, & 
Salminen, 2001; Schiller, 2007). A damaged intestinal lining allows infectious agents, toxic 
compounds, and macromolecules to pass through to the bloodstream. Symptoms of this increased 
intestinal permeability can include fatigue, diarrhea, and skin rashes. Ultimately, it can lead to 
many digestive disorders as well as seemingly unrelated illness, including chronic fatigue 
syndrome, eczema, migraine headaches, rheumatoid arthritis, and cancer. 
  Conversely, the healthy microflora provide protection against these harmful bacteria by 
strengthening the intestinal lining, competing with harmful bacteria for attachment to epithelial 
cells, producing antimicrobial compounds, and enhancing the intestinal immune system. Thus, 
maintaining a well-balanced intestinal microflora is important for reducing the risk of infections 
and supporting overall health. This may be accomplished through the therapeutic use of 
beneficial microorganisms, or probiotics such as bifidobacteria and lactic acid bacteria 
(Martinez-Villaluenga & Gomez, 2007). 
Lactic acid bacteria and bifidobacteria exert various beneficial effects on host health by 
controlling undesirable intestinal bacteria. Among reported beneficial effects of probiotics, are 
their inhibitory effect to putrefactive bacteria, reduction of fecal enzymes involved in cancer 
initiation, and reduction of serum cholesterol (Ibrahim & O‟Sullivan, 2000). The health 
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promoting benefits of these microorganisms is related to their ability to colonize in the intestinal 
tract. Attachment of a microorganism to intestinal tract is an important prerequisite for 
colonization. The adhesive ability to the intestinal mucus is one of the desirable properties that 
have to be selected for their specific use in commercial preparations (Bernet, Neeser, & Servin, 
1993; Ibrahim & O‟Sullivan, 2000; Kos et al., 2003). Probiotics, which can be used in animal 
feed and human food, are consumed microbial products containing abundant live and active 
cultures. They have been characterized as live microbial additive that provide beneficial effects 
to the host by improving its intestinal microflora balance. 
Since the efficacy of the use of probiotics is directly related to the number of live active 
culture cells consumed, it is important for human health condition to have a high number of 
culture cells in the food product. Characteristics of these microorganisms that also must be 
included are resistance to gastrointestinal acids, high attachment to human intestinal surfaces, 
colonization of human intestine, and production of antimicrobial substances (Casas & 
Dobrogosz, 2000). 
The health benefits and bifidogenic effect of prebiotics have been recognized from the 
last century (Martınez-Villaluenga & Gomez, 2007). Prebiotics are defined as non-digestible 
food ingredients that beneficially affect the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the colon and in consequence improve host 
health (Gibson & Roberfroid, 1995; Huebner, Wehling, & Hutkins, 2007). Technique that 
combines both probiotics and prebiotics has been called synbiotic. Synbiosis is a mixture of 
probiotics and prebiotics that beneficially affects the host by improving the survival and 
implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively 
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stimulating the growth and/or by activating the metabolism of one or a limited number of health-
promoting bacteria, and thus improving host welfare (Gibson & Roberfroid, 1995).  
  Shiitake mushroom (Lentinus edodes) extract contains many of oligosaccharides and 
polysaccharides (Kawakami, Minato, Tokimoto, Fujitake, & Mizuno, 2004), for this reason it is 
considered as prebiotics. Probiotics improve immune system and encouraged to grow by 
oligosaccharides and polysaccharides. Shiitake mushroom is an edible and medicinal mushroom 
popular in Japan, with a prominent activity in very small dosages (Chihara, Humuro, Maeda, 
Arai, & Fukuoka, 1970). Shiitake mushroom contains antitumor polysaccharides (Guo et al., 
2004). Most of clinical evidence for antitumor activity comes from polysaccharides lentinan 
(Maeda, Takahama, Kohara, & Yonekawa, 1996; Wasser, 2002). Many studies showed that 
polysaccharides from mushrooms do not attack cancer cells directly, but produce their antitumor 
effects by activating different immune responses in the host (Guo et al., 2004). Water-soluble 
extracts of shiitake mushroom was reported to inhibit the growth of Sarcoma 180 implanted in 
mice (Maziero, Cavazzoni, & Bononi, 1998). Therefore, colon bacteria may have an important 
role in carcinogenesis. The supply of indigestible oligosaccharides and polysaccharides is an 
important factor for the growth of intestinal microflora in human colon, such as lactobacillus and 
bifidobacteria (Gibson, 1999). According to that, shiitake mushroom is rich in oligosaccharides 
and polysaccharide; we suggest that it will be effective for the growth of intestinal lactic acid 
bacteria. 
Many cultures worldwide have long recognized that hot water decoctions from certain 
mushroom fungi can have health-promoting benefits. In China and Japan, in particular, many of 
these mushroom extracts have become important ingredients in traditional Chinese medicine. At 
least 270 species of mushrooms are considered to possess therapeutic properties, including 
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anticancer activity (Ying, 1987), and the term “medicinal mushrooms” is now gaining worldwide 
recognition. Many edible mushrooms used in traditional folk medicine, including Lentinus 
edodes. Mushrooms have been used not only as a source of food but medicinal resources as well 
(Maeda et al., 1996; Wasser, 2002). The medicinal properties of mushrooms have been proved 
through an intensive research conducted many countries. 
Intestinal bacteria can be divided on the basis of whether they can exert health promoting, 
benign or potentially harmful activities in their host (Gibson & Roberfroid, 1995). We have to 
consider the factors that may influence the flora composition in a manner than can impact upon 
health. The stimulated of probiotics bacteria (bifidobacteria and lactobacilli) should be a 
beneficial nature. To have these effects, prebiotics must be able to resistant digestive processes 
before they reach the colon and preferably persist throughout the large intestine such that 
benefits are apparent distally (Gibson, Probert, Van Loo, Rastall, & Roberfroid, 2004). 
Resistance to digestive processes as the criteria includes prebiotic resistance to gastric acidity, 
hydrolysis by mammalian enzymes, and gastrointestinal absorption. Figure 1.1 illustrates the 
criteria for classification of food ingredient as prebiotics (Wang, 2009). 
  
 
Resistance to the upper gut tract 
      
  
 
Fermentation by intestinal 
microbiota 
      Classification 
criteria 
 
Beneficial to the host health 
      
  
 
Selective stimulation of probiotics 
      
  
 
Stability to food processing 
treatments 
Adapted from Wang, 2009 
Figure 1.1. Criteria for classification of food ingredient as prebiotics 
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1.1. Objectives 
       The overall goal of this project is to develop a new technique that could be applied in the 
food industry to ensure food-grade probiotics that extend the viability longer, express α-
galactosidase/β-galactosidase, and to enhance the quality of dairy products overall. Specific 
objectives to be accomplished are as follows:  
1. To investigate the effect of mushroom extract/polysaccharides on growth of 
bifidobacteria and Lactobacilli in vitro.  
2. To determine the effect of shiitake mushroom extract on the growth, viability and α-
galactosidase/ β-galactosidase levels of bifidobacteria and Lactobacilli in milk during 
refrigerated storage. 
3. To investigae the impact of mushroom extract on viability and α-galactosidase/β-
galactosidase activities of bifidobacteria and Lactobacilli in yogurt products 
during refrigerated storage. 
1.2. Organization of Dissertation  
Chapter 2 of this dissertation presents background that mainly concerns with the 
probiotics properties of lactic acid bacteria and bifidobacteria with a focus on their use as a 
suitable vehicle for delivering health benefits to human. Chapter 3 details with the growth of 
Lactobacillus reuteri and bifidobacteria on MRS mixed with different level of SME. Chapter 4 
investigates the effects of different concentrations of SME mixed with skim milk on enhancing 
the survival and viability. Chapter 5 describes enhancing the viability of Lactobacillus reuteri 
DSM 20016 and Bifidobacterium breve grown on yogurt in the present of SME. Chapter 6 
summarizes the main conclusions of this dissertation and enumerates the recommendations for 
future researches.  
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CHAPTER 2 
Literature Review 
2.1. Milk Fermentation  
Milk and dairy product has been used throughout the human life. Mostly all civilization 
have developed such type of fermented milk product such as yogurt, buttermilk, and drinking 
yogurt, although the fermentation process was not defined very well. Yogurt is defined as 
product obtained by the fermentation of milk with cultures of streptococcus thermophilus and 
Lactobacillus delbrueckii and. Bulgaricus spp, however, yogurt-like products are made by 
substituting L. bulgaricus by other Lactobacillus species for the fermentation of milk or yogurt 
containing probiotic bacteria (Nikawa et al., 2004; Guarner et al., 2005).  
Recently dairy products process and its bacteria have received great attention after 
discovering the importance of viable and survival bacteria in food for health benefits. The first 
scientific study had been done by Metchnikoff to investigate the beneficial effects of fermented 
milk for human health. Later many studies have been spread all over the world describing the 
health benefit associated with the consumption of fermented milk and other products (Shin, Lee, 
Pestka, & Ustunol, 2000), LAB such as, Lactobacillus delbrueckii, Bbulgaricus and 
Streptococcus thermophilus do not adapted to human intestinal tract, and facing difficulty to pass 
through the digestive system (Klaver, Kingma, & Weerkamp, 1993). Therefore, to maximize the 
beneficial health effects by the fermented dairy products should be induce huge number in the 
human intestinal tract with Lactobacillus and Bifidobacterium species through fermented milk 
products (Reuter, 1990; Shah & Lankaputhra, 1997; Shah, 2001). 
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2.2. Probiotics 
 The human  intestinal tract plays a vital role in overall health, not only allowing life-
supporting nutrients to be absorbed, but also providing the first line of defense as a physical and 
immune barrier to food antigens or  microorganisms that human may ingest. Within this 
environment is a highly active society of hundreds different species of bacteria that can have 
both harmful and beneficial effects on your health (Isolauri, 2001). While it is imperative for 
one‟s overall health that the beneficial bacteria dominate, many factors can lead to an imbalance 
in favor of harmful bacteria, such as a poor diet, antibiotics, and contaminated food and water 
(Sullivan, 2001). 
A proliferation of unhealthy bacteria can damage human intestinal lining and lead to the 
production of carcinogenic compounds and intestinal symptoms such as bloating, gas, diarrhea, 
and abdominal pain (Isolauri, 2001). A damaged intestinal lining allows infectious agents, toxic 
compounds, and macromolecules to pass through to the bloodstream. Symptoms of this increased 
intestinal permeability can include fatigue, diarrhea, and skin rashes. Ultimately, it can lead to 
many digestive disorders as well as seemingly unrelated illness, including chronic fatigue 
syndrome, eczema, migraine headaches, rheumatoid arthritis, and cancer. 
Conversely, the healthy microflora provide protection against these harmful bacteria by 
strengthening the intestinal lining, competing with harmful bacteria for attachment to epithelial 
cells, producing antimicrobial compounds, and enhancing the intestinal immune system (Sullivan 
& Nord, 2005). Thus, maintaining a well-balanced intestinal microflora is important for reducing 
the risk of infections and supporting overall health. This may be accomplished through the 
therapeutic use of beneficial microorganisms, or probiotics such as bifidobacteria and lactobacilli 
(Tuohy, Probert, Smejkal, & Gibson, 2003). 
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The term probiotics originated from the Greek word meaning “for life”, but is defined by 
the Food and Drug Administration of the United States (FDA) and the World Health 
Organization as follows: “live microorganisms when administered in adequate amounts confer a 
health benefit on the host by promoting positive physiological changes” (Broekart & Walker, 
2006). Probiotics convey physiological changes in the gastrointestinal tract by increasing the 
amount of beneficial microflora in the stomach, colon, and intestines.  
Bacteria with probiotic effects have been observed in genera Saccrohymes, Clostridium, 
Enterococcus, and Bacillus; however, most probiotic bacteria originate from the genera 
Lactobacillus and Bifidobacterium (Table 2.1). These two genera make up 90% of the beneficial 
bacteria found in the human gut. In addition, their positive effects on the host are due to their 
classification as lactic acid bacteria, which is due to their ability to produce lactic acid as a result 
of carbohydrate fermentation. The production of lactic acid allows for more efficient metabolism 
in the gastric environment of the gut which contains high levels of acidic bile and pancreatic 
enzymes (Parvez, Malik, Ah Kang, & Kim, 2006). 
Probiotics organisms today have great benefit because they are alternative methods for 
the treatment of disease such as antibiotic. Balanced in intestinal microflora are necessary for 
maintaining the health of the host and the theory of probiotics suggest that one way to achieve 
this is to ingest exogenous bacteria and incorporate them into the colonic microflora. After 
antibiotic treatments, the frequency of dysbacteriosis is very high. The use of probiotic foods can 
maintain the balance of gut microflora and may help to control the effects of antibiotic therapy. 
Since the efficiency of the use of probiotics is directly related to the number of live and active 
culture cells consumed, it is important to increase the number of culture cells added to the food 
product. Characteristics of these microorganisms that must also be included are resistant to 
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gastrointestinal acids, highly attachment to human intestinal surfaces, colonization of the human 
intestine, and production of anti-microbial substances (Casas & Dobrogosz, 2000). 
Additionally, the culture should be active in terms of growth potential.  
Table 2.1 
Bacterial species reported to have probiotic applications 
 
Lactobacilli Bifidobacteria Other LAB “Non-lactic” 
L. acidophilus 
L. casei 
L. crispatus 
L. gallinarum
a
 
L. gasseri 
L. johnsonii 
L. paracasei 
L. plantarum 
L. reuteri 
L. rhamnosus 
B.adolescentis 
B. bifidum 
B. animalis 
B. breve  
B. infantis 
B. lactis
b 
B. longum 
 
Enterococcus faecalis
 a
 
Enterococcus faeciu 
 Leuconostoc mesenteroides
 c
 
    
Pediococcus acidilactici
 c
 
Lactococcus lactis
c
 
SporoLactobacillus inulinus
a 
Streptococcus thermophilus 
Bacillus cereus („toyoi‟)a, d 
Escherichia coli („Nissle, 
1917‟)d 
Propionibacterium 
reudenreichii
a, d 
 
Adapted from Holzapfel et al., 1998 
a 
Mainly used for animals. 
b 
Probably synonymous with B. animalis. 
c 
Little known about probiotic properties. 
d 
Mainly as pharmaceutical preparations 
 
2.3. Lactic Acid Bacteria (LAB) 
Lactic acid bacteria (LAB) are gram-positive non-sporing bacteria, which are 
physiologically diverse and mostly used as probiotics. LAB belongs to a heterogeneous group of 
bacteria that are generally united by common morphological, physiological and metabolical 
characteristics (Axelsson, 2004). Although, probiotic products may contain a variety of 
beneficial microbes, Bifidobacteria and Lactobacilli are the predominant genera incorporated, 
independently or in mixed combinations. Products contain probiotics are sold in two forms: dairy 
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foods, primarily yogurt and milk, or as dietary supplements in the forms of capsules, powders, or 
tablets. Common lactobacilli used as probiotics include Lactobacillus acidophilus, L. casei, L. 
bulgaricus, L. reuteri, L. brecis, L. cellobiosus, and L. fermentum. The mechanism of the action 
of probiotics (e.g. bifidobacteria and lactobacilli) relies on their metabolic end products, mainly 
organic acids. Organic acids may lower the human gut pH at which pathogenic microbes are not 
able to compete effectively (Figure 2.1). The complex and dynamic microbial environment 
shows an overview of the potential activities of probiotic micro-organisms might influence the 
intestinal microflora (O‟Toole & Cooney, 2008). Dietary intake supplemented with probiotic 
cultures may modulate the intestinal microflora or change its metabolic properties by 
competition for nutritional substrates Lactic acid bacteria are acid-tolerant, which enables them 
to continue fermentation of carbohydrates under low pH levels (Axelsson, 2004). 
  
Adopted from O‟Toole & Cooney, 2008 
 
Figure 2.1. Interactions of probiotics and the normal microflora of the host to prevent 
colonization of opportunistic and pathogenic microorganisms 
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Probiotics bacteria are manufactured in an array of products, such as various dietary 
supplements and functional foods. Probiotic dietary supplements are easily purchased at 
grocery/health food stores or on the internet. The goal of these products is to maintain the 
balance of microflora in the human intestinal tract, by meeting the following criteria outlined by 
the FDA: (a) gastrointestinal adherence, (b) bacteriocin production, (c) assimilation of 
cholesterol, (d) high fecal enzyme activity, (e) antimutagenicity, and (f) small bowel bacterial 
growth (Doron & Gorbach, 2006). Probiotic supplements contain freeze dried bacteria 
administered to the host orally in tablet, powders, or capsule forms, which contain one to two 
billion viable bacteria per gram. Probiotic supplements often are packaged in nitrogen flushing 
glass bottles at 4°C, containing no hormones or other chemical additives (Walker, 2008).  
This probiotic is generally recognized as safe (GRAS) by FDA (Speck, Dobrogosz, & Casas, 
1993). L. reuteri has been incorporated into commercial probiotics and functional foods (Martoni 
& Bhathena, 2008). New applications have been proposed to use L. reuteri as a feed additive 
(Casas-Pérez, 1996) and food supplement (De Boever, Wouters, Vermeirssen, Boon, & 
Verstraete, 2001), as well as in fermented cereals (Charalampopoulos, Pandiella, & Webb, 2002) 
and buttermilk production (Rodas, Angulo, Cruz, & Garcia, 2002). It has been reported that the 
populations of L. reuteri strains are less variable because productions of reutericyclin appears to 
contribute markedly to their stability and persistence in sourdough fermentation (Ganzle & 
Vogels, 2003). L. reuteri had the highest viability after 30 d of storage and during fermentation 
of non-dairy, oat-based products (Martensson, Oste, & Holst, 2002). Although L. reuteri has a 
wide variety of beneficial effects on human health, it has a low occurrence in commercial dairy 
foods. Different studies on incorporation of probiotics microorganisms in dairy food have been 
reported. In this context, high growth rate and acidification ability in milk have been reported for 
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L. reuteri (Xanthopoulos, Litopoulou-Tzanetaki, & Tzanetakis, 2000). Also the report showed 
that if high cell concentrations are reached, better acidification may be attained (Kulozik & 
Wilde, 1999). In addition, a number of research groups have focused their attention on 
improving lactic acid bacteria high cell production via fermentation by exploiting novel 
bioreactors that permit the exchange of the medium to prevent lactic acid accumulation and 
therefore growth inhibition.  
2.3.1. Lactobacillus. Lactobacillus is one of the most common genera of LAB found in 
nature. It is a gram positive, rod shaped, and facultative anaerobic genus of bacteria. The genus 
Lactobacillus is considered heterogeneous, (Schleifer & Stackebrandt, 1983) and the most acid-
tolerant of LAB (Kashket, 1987). Lactobacillus has widespread applications in the food industry. 
Previously, Lactobacillus was arranged into three groups: Thermobacterium, 
Streptobacterium, and Betabacterium (Orla-Jensen, 1921). However, since the previous groups 
did not represent formal subgenera, this classification was removed from Bergey‟s Manual 
(Kandler & Weiss, 1986). Instead, metabolic characteristics were used to divide the different 
species of lactobacilli into the three groups (obligatory homofermenters, facultative 
homofermenters and obligatory heterofermenters) described previously. Most species of 
Lactobacillus genus are homofermentive, but some are considered heterofermentive (Madigan & 
Martinko, 2006).  
2.3.2. Habitats of Lactobacillus. Lactobacilli are considered very fastidious, and 
therefore they require complex media for growth. Fermentable carbohydrates, proteins, nucleic 
acid derivates, fatty acids, vitamins and metal ions are generally needed in the growth media of 
lactobacilli. Thus, in nature lactobacilli are associated with nutrient-rich media like plant 
material, milk and milk products, meat and meat products, fish, and the oral cavity, GI tract and 
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vagina of humans and animals (Kandler & Weiss, 1986). Certain species, such as L. plantarum 
and L. casei, can be found in almost any of the aforementioned habitats, whereas other species 
have restricted niches such as L. reuteri, which is found mainly in the GI tract of humans and 
animals. Lactobacilli are widely used in the food industry because they are considered GRAS by 
the FDA (Speck et al., 1993).  
2.3.3. Bifidobacteria. Bifidobacterium is classified into hundreds different species. 
Bifidobacterium colonies are described as being shiny, with convex shape, circular form, and 
soft. They are cream to white in color (Valazquez & Feirtag, 1997). The morphology of 
bifidobacteria is characterized as rods of different shapes, and in single form or branched or “Y” 
groupings and as coccoidal regular cells (Reuter, 1963). Bifidobacteria are gram-positive 
anaerobic bacteria. The most commonly used and reported probiotics include two genera; 
Lactobacillus (L. acidophilus, L. casei, L. bulgaricus) and Bifidobacteruim (B. bifidum, B. 
logum, B. breve, B. infantis, B. animalis, and other Bifidobacterium species). Both genera are 
found in the normal intestinal flora at relatively low levels in healthy human adults. 
Bifidobacteria constitute up to quarter of the normal flora in adults and more than 90% in 
newborn. The increased level in infants has been associated with the practice of breastfeeding 
(Biavati, Castagnoli, & Trovatelli, 1986). Shah, (2001) mention that there are 56 species of 
Lactobacillus and 29 species of Bifidobacterium, used worldwide in dairy products The main 
species of Lactobacillus and Bifidobacteria had been reported in recent publications such as; L. 
lactis, L. casei, L. paracasei and more. B. longum, B. adolesentis, B. breve, and B. bifidum 
(Shah, 2001). Bifidobacteria exert various beneficial effects on host health by controlling 
undesirable intestinal bacteria. Among reported beneficial effects of bifidobacteria, are their 
inhibitory effect to putrefactive bacteria, reduction of fecal enzymes involved in cancer initiation, 
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and reduction of serum cholesterol (Ibrahim & O‟Sullivan, 2000; Koop, Valentijn-Benz, Nieuw, 
Amerongen, Roukem, & De Graaff, 1989). The health promoting benefits of these 
microorganisms is related to their ability to colonize in the intestinal tract. Attachment of a 
microorganism to intestinal tract is an important prerequisite for colonization. The adhesive 
ability to the intestinal mucus is one of the desirable properties that have to be selected for their 
specific use in commercial preparations (Bernet et al., 1993; Ibrahim & O‟Sullivan, 2000; Koop 
et al., 1989; Petr & Rada, 2000). 
2.3.4. Natural habitat of bifidobacteria. The typical habitat of bifidobacteria is human, 
warm-blooded animal and honeybee intestinal tract (Scardovi, 1986). Bifidobacterium spp., are 
among the most common microorganisms in the human gut (Sghir et al., 2000). In breast-fed 
infant bifidobacteria form about 90% of their total microflora (Harmsen et al., 2000). Because 
the stomach is highly acidic, most bacteria settle in the small and large intestines, and are present 
in particularly large quantities in the colon. Under normal circumstances, bacteria in the 
digestive system live in balance and harmony, but factors such as poor diets and overuse of a 
variety of medications can throw the system off balance and lead to a host of difficulties (Walker 
& Duffy, 1998). Proper protection and nourishment of our healthy bacteria, and then, are very 
important to good overall health. Bifidobacteria in dairy product, are not growing as fast as 
lactobacillus, and they required certain growth factor, such as bifidogenic, these carbohydrates 
found in human milk (Liepke et al., 2002). 
It has been said that there are more bacteria in our digestive systems than there are cells 
in our body. The colon alone contains trillions of bacterial cells. Bacterial cells can be classified 
in one of four hundred to five hundred types both healthy and dangerous. Twenty types make up 
three-quarters of the total and are present in large amounts. 
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The two strains of bacteria recognized as the most important to health are Lactobacilli 
and bifidobacteria. Lactobacilli are concentrated in the small intestine and bifidobacteria reside 
primarily in the large intestine, mainly the colon. Our relationship with these bacteria can be 
described as symbiotic, we provide them with warm dark environments where they can flourish, 
and they provide us with disease protection and improved health. 
Several authors studies the distribution of bifidobacteria during various period of life, 
from infants (breast-fed or not) to adult (Lerche & Reuter, 1962). New born are devoid of an 
intestinal flora but bifidobacteria appear on the first week of life and constitute one of the most 
numerous bacterial groups, amounting to 10
10
/g of wet faeces (Mitsuoka, 1978; Mitsuoka, 1984) 
originally, it was thought that bifidobacteria between breast-fed and infants whereas in bottle-fed 
infant Lactobacillus acidophilus was supposed to be the most commonly found organism. 
However, according to Knol et al. (2005), the differences in occurrence and number of 
bifidobacteria between breast-fed and bottle-fed infants were not significant. The principle 
difference between both was that in bottle-fed infants the numbers of enterobacteriaceae, 
streptococci and anaerobes other than bifidobacteria were significantly higher than in breast-fed 
infants.  
2.4. Probiotics and Associated Health Benefits 
Research shows that probiotics have beneficial health effects which impact all ethnic 
groups and ages (Holzapfel, Haberer, Snel, Schillinger, & Huis, 1998) (see Figure 2.2). The first 
effect of probiotics can be shown within the first week of life where Bifidobacterium is the 
dominant bacterial genera passed to infants via breast feeding (Holzapfel et al., 1998). After the 
first month of life, the amount of probiotic bacteria begins to decrease and other genera of 
bacteria such as Enterobacteriaceae, Lactobacillus, and Clostridia become more dominant. Over 
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the average human lifespan there is an accumulation of over four hundred different strains of 
bacteria in the gastrointestinal tract (GIT) (Holzapfel et al., 1998).  
 
Source: http://abbottnutrition.com/Education/Prebiotics 
 
Figure 2.2. Effects of beneficial bacteria 
                  
Probiotics aid in proper functioning of the GIT by: (1) breaking down food components, 
(2) producing certain B vitamins and digestive enzymes, and (3) stimulating the immune 
response (Holzapfel et al., 1998). Probiotics are vital for immune modifications because of their 
role in the production of immunoglobulin‟s A and E, B and T cells, and the prevention of 
pathogenic microorganisms which can cause illness (Perdigon, 2005). Furthermore, the intake of 
probiotics benefits innate immune responses such as: (1) cell-mediated immunity, (2) the 
secretion of specialized gut antigens, and (3) the production of T helper, and T receptor cells 
(Perdigon, 2005). As researchers have begun to understand the importance of probiotics in the 
prevention of disease, it is important to closely examine some of the illnesses that the intake of 
probiotics is instrumental in preventing. 
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2.4.1. Probiotics in relief of lactose intolerance and diarrhea. The use of probiotics 
has been as a natural therapy for the alleviation of lactose intolerance and diarrhea. Lactose 
intolerance is a condition characterized by the inability of the body to metabolize the sugar 
lactose due to the absence of lactase which is a key enzyme located in the large intestinal tract 
(Vesa, Seppo,  Marteau, Sahi, & Korpela, 1998). With lactase being absent, lactose, cannot be 
metabolized or absorbed by the intestinal wall where lactose enters the bloodstream to allow for 
digestion in the gastrointestinal tract (Matthews, 2005). If not metabolized, the sugar, lactose, 
remains in the intestines where fermentation occurs causing gas, cramps, bloating, and diarrhea 
(Garro, de Valdez, Oliver, & De Giori, 1996).  
In one study published in 2002, where probiotics were used as a form of treatment against 
lactose intolerance (Levri, Ketvertis, Deramo, Merenstein, & D‟Amico, 2005). The results of this 
investigation suggested 2002, where probiotics were used as a form of treatment against lactose 
intolerance (Levri et al., 2005). Levri and his team found that, oral probiotics do have a 
beneficial effect on lactose-induced symptoms and the amount of lactose present in the subject 
body. Of the studies, nine measured breath hydrogen where 66% showed positive results in the 
decrease of symptoms, while only 34% showed no improvement with probiotics. The 
investigation concluded that probiotic products containing a cocktail formula of L. rhamnosus 
GG and L. reteuri can alleviate the symptoms and signs of lactose intolerance in adults (Levri et 
al., 2005). Along with lactose intolerance, probiotics have also been used in the treatment 
ofdiarrhea. Diarrhea is a condition caused by viral infections and/or a combination of parasites or 
bacterial toxins (Schiller, 2007). 
Diarrhea often must be treated medically when it occurs in infants and young children if 
it is moderate to severe. Medical attention is also required for diarrhea when accompanied with 
22 
 
 
 
fever, anemia, loss in weight, and serve abdominal pains (Alam & Ashraf, 2003). There are 
many types of diarrhea such as secretary, osmotic, inflammatory, infectious and motility-related 
diarrhea impacting a great number of people mostly (Alam & Ashraf, 2003).  
Haung and colleagues (2002) found that probiotics can decrease the duration of acute 
diarrhea by one day in children. In addition, the study also showed that probiotics decrease the 
incidence of malabsorption associated with diarrhea in infants and young children. Furthermore, 
a meta-analysis study showed that probiotic products containing Sacchomyces boularditi 
decrease antibiotic-associated diarrhea in children, adults, and soldiers (Szajewska & Mrukowitz, 
2001). The study concluded that the intake of probiotics have been shown to reduce risk and 
incidence in developing regions such as Africa, Asia, and the Caribbean. 
2.4.2. Potential role of probiotics in colon cancer prevention. Colon cancer is a disease 
where the growth of abnormal cells proliferates and forms tumors. Colon cancer affects the large 
intestines centralizing in the colon and the rectal areas of the gastrointestinal tract. Although, for 
years researchers have hypothesized about the cause of colon cancer, little is known about the 
actual cause. There is a wide spread belief among cancer biologists that the disease is caused by 
polyps or small pre-cancerous growths that begin in the colon and spread into the rectal region. 
Colon cancer is prevalent in individuals that eat a high fat diet, smoke, and individuals that have 
a genetic predisposition (Rafter, 2003).  
Colon  cancer is diagnosed through a colonoscopy, which is a procedure that examines 
the inside of the colon and rectum. Furthermore, a biopsy can be performed where a pathologist 
examines the colon and rectum tissue under a microscope to see if the tissue is cancerous (Rafter, 
2003). Colon cancer discovered at its early stages is treatable with radiation and chemotherapy, 
but in most cases surgery is required to remove the tumor (Rafter, 2003). With colon cancer 
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being the third most prevalent form of cancer, physicians believe that the ingestion of probiotics 
can reduce the risk of acquiring colon cancer. Researchers believe the ingestion of foods 
containing lactic acid bacteria aid in the formation of short chain fatty acids, which are vital in 
the production of the chemopreventive enzymes associated with the reduction of colon cancer 
(Wollowski, Rechkemmer, & Pool-Zobel, 2001).  
In addition, probiotics assist in the reduction of colon cancer by the formation of 
metabolites. The process occurs through the breakdown of polysaccharides, starch, and fiber, 
which enhances the formation of short chain fatty acids which is vital in decreasing the pH of the 
colon, and then reducing the risk of tumor formation (Wollowski et al., 2001). Research shows 
that probiotics intake decreases the amount of somatic mutations associated with colon cancer. In 
vivo models supplemented with probiotics have also been shown to (1) deactivate genotoxic 
carcinogens (2) prevent DNA damage, and (3) prevent aberrant foci cell mutations associated 
with colon cancer (Rafter, 2003). 
2.4.2.1. Impact of probiotics on immune function. An improperly functioning immune 
system can result in several immunological disorders such as autoimmune diseases, immune 
deficiencies and allograft rejection. These malfunctions can often cause fatal injuries and, in 
severe cases, death. In order to prevent the immunological disorders from occurring, researchers 
have performed in vitro, in situ, and in vivo studies to understand the chemical and physiological 
properties of the immune system and how probiotics affect organs. With the recent surge in 
popularity of probiotics, researchers have begun to investigate their importance on immune 
response. This is achieved through the study of passive immunity via saliva, gastric acid, mucus, 
intestinal flora, and several other factors that fight against antigens and aid the GIT main 
protective barricade, the gut mucosal barrier.  
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The importance of the gut mucosal barrier on the host and immune enhancement by 
probiotics can first be observed at birth. During postnatal development in the first months of life, 
there is a maturing of the gastrointestinal tract leading to the production of mucosal proteins, 
digestive enzymes, and secretion of hydrochloric acid occurs and allows for gastrointestinal tract 
immunity (Isolauri & Sutas, 2001). As a child ages and the body develops a tolerance against 
antigens, due to the growth of gut epithelial cells, which allow for mucosal immune response 
during the first years of life (Isolauri & Sutas, 2001). As a child matures, the intake of dairy 
products supplemented with probiotics has an added importance in their ability to develop large 
intestinal lymphoid tissue. These tissues represent the largest mass of lymphoid tissue in the 
human body, which affect the regulatory events of the intestinal immune response. Furthermore, 
this allows for the gastrointestinal tract to efficiently produce mucosa and secretory sites within 
the intestinal wall (Isolauri & Sutas, 2001). The gut lymphoid tissue also allows for the 
production of antibodies in the respiratory tract, salivary, and mammary glands. As a child 
matures to adulthood, probiotics play an equally important role in immune enhancement (FAW, 
2002). Bifidobacterium spp. increase adherence of gut lymphoid tissue and gastrointestinal 
microflora in the maintenance of normal immune function (FAW, 2002). 
In addition, probiotic products supplemented with bacteria from the genus Lactobacillus 
have been shown to have the most wide spread effect influencing chronic vaginitis, urogenital 
infections, Crohn‟s disease, and diarrhea. Moreover, supplementing products containing 
Lactobacillus can increase: (1) the secretion of IgA, (2) interleukin-6 and 10, (3) the production 
of cytotoxic T cells, (4) T helper cells 1 and 2, and (5) the production of dendritic cells (Marteau, 
2001). In addition, the intake of probiotics is vital in the development of a healthy and efficient 
immune system in children and adults. Without the intake of probiotics the immune system will 
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not be able to productively and efficiently fight against disease as efficiently without the intake 
of probiotics. 
2.4.2.2. Possible treatment of inflammatory bowel disease (IBS). One of the most 
common gastrointestinal disorders that affect individuals in the United States is IBS. The 
intestinal disorder is characterized by abdominal pain, cramping or bloating, diarrhea, and/or 
constipation (Gilkin, 2005). IBS is distinguished from other gastrointestinal disorders because 
physicians find no change in physiological structure of the body such as inflammation or tumors. 
However, physicians notice that the disorder is related to an abnormality between the brain and 
the intestinal tract where abnormal contractions result from different signals between the brain 
and the intestines. Once diagnosed, IBS is very manageable.  
One aspect that has been researched is the importance of probiotics in the treatment and 
reduction of IBS (Camilleri, 2006; Alazzeh, Ibrahim, Song, Shahbazi, & AbuGhazaleh, 2009). 
Probiotics such as Lactobacillus acidophilus and Bifdobacterium infantis found in milk products 
reduce the symptoms of IBS by decreasing the amount of gas, cramping, and bloating associated 
with the disorder (Holzapfel et al., 1998; Krammer & Schlieger, 2005; Heyman, 2006). 
Furthermore, probiotics along with antibiotics such as ciprofloxacin show a decline in the 
amount of symptoms associated with IBS (Camilleri, 2006). A study performed at the University 
of Helsinki showed that a combination of probiotic strains Lactobacillus rhamnosus, and 
Bifidobacterium breve showed a 42% decrease in abdominal pain, distension, flatulence, and 
rumbling of the stomach compared to patients that did not have the probiotic treatment (Penny et 
al., 2008). Probiotic intake decreases the production of toxic short chain fatty acids, as well as 
the formation of intestinal hydrogen in IBS patients (Penny et al., 2008). Furthermore, probiotic 
intake can reduce side effects of a decrease in bacterial enzymes by reducing the amount of small 
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intestine bacterial overgrowth and increase of probiotic bacterial adherence to the gut (Korpela, 
2006). The influence of probiotics on IBS can also be noted in the reduction of symptoms 
associated with the disease such as abdominal pain, bloating, gas, and constipation (Gilkin, 
2005).  
Technique that combines both probiotics and prebiotics has been called symbiotic, which 
is a mixture of probiotics and prebiotics that beneficially affects the host by improving the 
survival and implantation of live microbial dietary supplements in the gastrointestinal tract. By 
selectively stimulating the growth and/or by activating the metabolism of one or a limited 
number of health-promoting bacteria and thus improving host welfare (Gibson & Roberfroid, 
1995).  
2.5. Prebiotics 
A prebiotic is a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microflora that confers benefits upon host 
well-being and health (Roberfroid, 2007). There are some factors affect the composition of 
gastrointestinal tract microflora in humans, such as age, colonization,  health, nutritional 
requirements, and immune system condition of the host, the large intestinal tract pH, and the 
correlation between flora components and availability of prebiotic material in the human 
gastrointestinal tract. According to these factors, it is probably the amount and type of growth 
substrate that has the most effect. Non-digested food residues or prebiotics in the upper part of 
gastrointestinal tract, as well as endogenous materials like mucins, epithelial cells, and bacterial 
remaining products, contribute to the pool of metabolizable substrates (Gibson & Roberfroid, 
1995). Dietary intake may exert a major influence on gastrointestinal tract microflora and their
 
development. 
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2.5.1. Concept of prebiotics. The human gastrointestinal tract microflora influences the 
health and happiness. The use of diet to fortify certain gastrointestinal flora components is a 
popular current aspect of functional food sciences. The food containing fibers plays as major 
fermentable diet in the human gastrointestinal. Examples for these kinds of food are 
carbohydrate-based materials such as, lactose, oligosaccharides, food sweeteners, and other non-
absorbed sugars. There is a small contribution from nitrogen-based materials like legumes, 
amino acids, and some dietary lipids may also passed to  the large intestinal tract in a 
metabolizable processing. Prebiotics are foods that stimulate the growth of bifidobacteria and 
lactobacilli in the gastrointestinal tract, and thereby, increase the body‟s natural resistance to 
fight harmful bacteria (Kim & Rajagopal 2000; Ibrahim et al., 2009). Also prebiotic 
carbohydrates may have less specific benefits because they are fermented in the human large 
intestinal tract. The prebiotic carbohydrates that have been evaluated in humans at the present 
time largely consist of oligosaccharide and polysaccharide. There is proved evidence that these 
are not digested by normal human enzymes, but are readily fermented by anaerobic bacteria in 
the large intestine. Through fermentation in the large intestine, prebiotic carbohydrates yield 
short-chain fatty acids, stimulate the growth of many bacterial species in addition to the selective 
effects on lactobacilli and bifidobacteria, they can also produce gas (Cummings & Macfarlane, 
2002). Potentially, the most important effect of prebiotics carbohydrates is to support the human 
body‟s defense of invading pathogens and, thereby, prevent of diarrhea (Figure 2.3). 
The gastrointestinal tract of infants is cultured mostly by organisms oriented from the 
mother‟s vagina and feces and from the environment. After birth, the digestive system tract is 
rapidly colonized by bacteria, but probiotic bacteria gradually become a dominant as main 
organisms, and continue to be super bacteria in the first few months after delivery, in breast-fed 
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infants (Ishibashi & Hayasawa, 1997). The population of probiotics in gastrointestinal tract in 
bottle- fed infants, gradually decreased in number from the time of weaning, and bacteria such as 
anaerobic streptococci and E. coli will exist in highest numbers (Rotimi & Duerden, 1981). 
These bacteria may subsequently create a highly new environment that allows the growth of 
competitive an aerobic species. Differences in microflora are also observed by culturing the fecal 
flora of breast-fed and bottle-fed infants (Mitsuoka, 1978). The high number of Lactobacillus 
and Bifidobacterium is a sign of possible explanation for the health advantages. The change of 
dietary intake may influence the microflora composition and consequences of that is the health 
status of human. The use of probiotics, prebiotics, and synbiotics may all be feasible. Ben et al. 
(2004) proved that the addition of prebiotics to infant formula can increase beneficial bacteria in 
the digestive system to levels similar to that mother milk. In addition, prebiotics can help in 
laxation to be like those of breastfed infants.  
 
Source: http://abbottnutrition.com/Education/Prebiotics 
 
Figure 2.3. How prebiotics work 
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2.5.2 Prebiotics criteria and hypothesis for mechanisms. The criteria used for 
classification of a food component as a prebiotic should be resistance to digestion processing, 
hydrolysis and fermentation by colonic microflora, and most importantly, selective stimulation 
of growth of one or a few number of bacteria in the feces. Resistance to digestion should be 
proved in the laboratory (Macfarlane & Cummings 1999; Thibault, Aubert-Jacquin & Goulet, 
2004; Roberfroid, 2007). To show and quantify hydrolysis and fermentation by colonic 
microflora, human fecal samples are a valuable surrogate for colonic content. Prebiotics are a 
unique concept in human nutrition and health condition for which, as is often the case with a new 
application, many health and physiological claims have already been made. Table 2.2 shows 
these claims. Central to all claims is the effect on the microflora, which in turn should work 
hardly and strong to resist the pathogen invasion in the large bowel, and a reduction in diarrheal 
diseases (Cummings & Macfarlane, 2002).  
Table 2.2 
Claimed gastrointestinal effects of prebiotics 
Gastrointestinal  Effects 
Through fermentation 
in the large bowel 
 Production of short-chain fatty acids and lactate 
 Gas, mainly CO2 and H2 
 Increase in biomass 
 Increased fecal energy and nitrogen 
 Mild laxative properties 
On the microflora 
 Selective increases in bifidobacteria and lactobacilli in planktonic 
and biofilm communities 
 Reduction in clostridia 
 Increase in colonization resistance to pathogens 
 Potential benefit in preventing pathogen invasion 
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Table 2.2 (cont) 
 
Gastrointestinal  Effects 
Small intestine 
 Osmotic effect of low molecular weight prebiotics (DPS, 4) 
which occasionally causes diarrhea 
 Improved calcium, magnesium and iron absorption 
 Interaction with mucus to change binding sites for bacteria, lectins 
etc. 
Mouth  Protection against caries 
Other effects 
 Bile acid metabolism-no consistent changes reported 
 Variable effects on microbial enzymes with potential to affect 
carcinogenesis 
 Stimulation of apoptosis 
 
The composition and activities of the large intestinal tract microflora is essential for 
health-promoting activities are optimized remains as a major in functional food development. 
The prebiotics effect is an environmental effect and needs to be treated as such. The 
demonstration of this effect requires a much more qualitative and quantitative analysis of the 
gastrointestinal tract microflora and its modulation by the prebiotics treatment. These methods 
are being extensively applied to human large intestine tract‟s environment to detect fundamental 
changes in colonic microflora composition and to correlate them with health benefits that are 
possibly not to be limited to gastrointestinal physiology. Systemic effects of prebiotics should be 
identified and followed by further investigation. 
As long as shiitake mushrooms consider as prebiotics, the potential application of 
shiitake mushroom extract is required to be investigated as functional food for reducing the risk 
of colon carcinogenesis as well as to improve. Lentinan from Shiitake has been proved as an 
anticancer therapy by the Japanese FDA. Lentinan as extract of shiitake extract has shown some 
effect on cancer cells affected bowel, liver, stomach, ovarian, and lung (Mohammad, Faruqi, & 
Mustafa, 2009). In many studies lentinan stimulated the production of T lymphocytes and natural 
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killer cells (Mizuno, Kawakami, Hashimoto, Ashida, & Minato, 2001; Wesser, 2002). Shiitake is 
rich in several antioxidants like selenium, uric acid, and vitamin A, E, and C as well as vitamin 
D. The high proportion of people susceptible to colon cancer, are those have high population of 
somatic mutations occurring during the lifetime of an individual, could be prevented by 
eliminating these mutations.  
2.6. Shiitake Mushroom 
2.6.1. Overview. When most people hear the word “mushroom” they picture just one 
variety: “the cultivated white mushroom, fruit of the fungus Agaricus bisporus.” But other 
varieties are appearing in local markets, including shiitake, a darker and stronger-flavored cousin 
of the common button mushroom (see Figure 2.4). The shiitake (Lentinula edodes), begins life as 
an invisible network of thin, spidery threads, which grow through the dead tissue of various 
hardwoods such as oak, beech, or chestnut. The mycelia digest the wood and convert it into 
fungal tissue (Witzany, 2008). It is believed that Chinese growers introduced shiitake cultivation 
techniques to Japanese farmers, who named the mushroom and were later responsible for its 
spread eastward (Chang, 1999). Composed of sawdust and supplemented with millet and wheat 
bran are a good medium for shiitake to grow. Also, environmentally controlled houses allow for 
the manipulation of temperature, humidity, light, and the moisture content of the medium to 
produce the highest possible yields. Mushrooms consume water and nutrients from their 
environment and begin to reproduce. The medium that mushroom mycelium grows on is usually 
called substrate. Before the mushroom can start to form fruit bodies the mycelium colonizes the 
substrate fully and when the environmental conditions are right the mushroom emerges to 
produce more spores. Mushroom cultures can be stored for prolonged periods of time to preserve  
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the unique strains that mushrooms produce; some strains are desired for their rapid growth, 
resistance to disease and other characteristics. Mushrooms are truly unique organisms. Their full 
potential in recycling agricultural wastes and tree stump decomposing has yet to be taken 
advantage. Some mushrooms like the Shiitake even boast cancer fighting properties. 
 
Photo courtesy Dr. Omon Isikhuemhen, NC A&T 
 
Figure 2.4. Shiitake mushroom 
 
2.6.2. Production and consumption of shiitake mushroom. Shiitake were originally 
treasured Asian mushrooms with great flavor, taste and an enticing aroma. They are also known 
for their medicinal benefits in strengthening the immune system. Asian populations worldwide 
continue to favor Shiitake, whether fresh or dried. Factors that may affect Shiitake consumption 
include consumers‟ ethnic and cultural backgrounds, tastes for food, ages, sex, perception and 
knowledge of mushroom products, mushroom image and consumers‟ income. Shiitake appeals to 
health-conscious populations as well as vegetarians for its attributes of high nutrition, quality 
protein, essential amino acids, low calorie content and health benefits. In regions where edible 
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mushrooms are not a traditional food, demand for mushrooms such as Shiitake depends on the 
continuous effort of mushroom producers to educate consumers. 
The benefits of modern sawdust cultivation include a consistent market supply through 
year round production to meet consumer demand. Moreover, sawdust cultivation is a means to 
use agricultural wastes (Lopez, Valencia, & Chang, 2004) and spent mushroom substrates to 
generate food. World production of mushrooms is dominated by species that are edible and have 
medicinal benefits. Shiitake now ranks number one in specialty production. Current trends in 
mushroom production and consumption turn toward fresh product, particularly in the main 
markets of the U.S. and Europe (Zhang, 2004).  
2.6.3. Lentinan. Lentinan is a polysaccharide derived from the vegetative parts of the 
edible shiitake mushroom. It is the cell wall constituent extracted from the fruiting body or 
mycelium of L. edodes and is not generally associated with side effects. See Figure 2.5 for the 
chemical structure of β-glucan lentinan. 
 
Adopted from Nakano et al., 1999. 
 
Figure 2.5. Chemical structure of β-glucan lentinan 
 
2.6.4. Active hexose correlated compound (AHCC). Active hexose correlated 
compound (AHCC), extracted from shiitake mushrooms, which contains α-glucan rich in 
ploysaccahrides and fibers. AHCC has been shown to induce enhancement of human health, by 
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immune responses, including enhanced natural killer activity (Aviles et al., 2003; Weisbuger, 
1977). Research proved that AHCC possesses many physiological activities, such as Increasing 
resistance to pathogens, producing an anti-cancer, and enhancing immune function.  
2.6.5. Medicinal value. An extract (Lentinan) from Shiitake has been licensed as an anti-
cancer drug by the Japanese FDA. Lentinan has shown some effect on bowel cancer, liver 
cancer, stomach cancer, ovarian cancer and lung cancer (Maeda et al., 1996; Wasser, 2002). 
Lentinan stimulates the production of T lymphocytes and natural killer cells and can potentiate 
the effect of AZT in the anti-viral treatment of A.I.D.S (Guo et al., 2004). Shiitake is rich in 
several anti-oxidants (Selenium, Uric acid and Vitamin A, E, and C) as well as Vitamin D. 
Shiitake mushrooms may also lower blood pressure in those with hypertension, lower serum 
cholesterol levels, increase libido, and stimulate the production of interferon which has anti-viral 
effects, and has proven effective against hepatitis in some cases. Shiitake mushroom (Lentinus 
edodes) extract contains many of oligosaccharides and polysaccharides (Kawakami et al., 2004), 
for this reason, is considered as prebiotics. Probiotics improve immune system and are 
encouraged to grow by oligosaccharides and polysaccharides. Most of clinical evidence for 
antitumor activity comes from polysaccharides lentinan (Maeda et al., 1996; Wasser, 2002). 
Many studies showed that polysaccharides from mushrooms produce their antitumor effects by 
activating different immune responses in the host (Guo et al., 2004). Water-soluble extracts of 
shiitake mushroom was reported to inhibit the growth of Sarcoma 180 implanted in mice 
(Maziero et al., 1998). Therefore, colon bacteria may have an important role in carcinogenesis. 
The supply of indigestible oligosaccharides and polysaccharides is an important factor for the 
growth of intestinal microflora in human colon, such as lactobacillus and bifidobacteria 
(Velazquez & Feirtag, 1997; Gibson, 1999). 
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Shiitake mushroom has been used in Japan and China as both a food and medicine for 
thousands of years. It is now commonplace throughout the world. Extracts of these mushrooms 
are now being incorporated into over-the-counter dietary supplements designed to improve the 
status of the immune system. According to that, shiitake mushroom is rich in oligosaccharides 
and polysaccharide; we suggest that it will be effective for the growth of lactic acid bacteria. 
 Many cultures worldwide have long believed that hot water decoctions from certain 
mushroom fungi could support health-promoting benefits. In China and Japan, in particular, 
many of these mushroom extracts have become important ingredients in traditional Chinese 
medicine. At least 270 species of mushrooms are considered to possess therapeutic properties, 
including anticancer activity (Ying, 1987), and the term “medicinal mushrooms” is now gaining 
worldwide recognition. Many edible mushrooms used in traditional folk medicine, including 
Lentinus edodes. Mushrooms have been used not only as a source of food but medicinal 
resources as well (Maeda et al., 1996; Wasser, 2002). The medicinal properties of mushrooms 
have been proved through an intensive research conducted many countries. 
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CHAPTER 3
1
 
Shiitake Mushroom (Lentinus Edodes (Berk.) Singer) Extract Enhance the Growth of 
Lactic Acid Bacteria and Bifidobacteria in vitro 
3.1. Introduction 
 
Probiotics create a balance between beneficial microflora and pathogens that could 
invade the gastrointestinal tract such as Clostridium difficile, Escherichia coli, and Salmonella 
spp. Probiotics are used in the alleviation of gastrointestinal disorders, such as infectious diarrhea 
and irritable bowel syndrome cramps (Garro et al., 1996). Prebiotics are defined as non-
digestible food ingredients that beneficially affect the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon and in consequence improve 
host health (Gibson & Roberfroid, 1995). Technique that combines both probiotics and 
prebiotics has been called synbiotic (Indrio et al., 2009). Synbiosis is a mixture of probiotics and 
prebiotics that beneficially affects the host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal tract.  
Recently, public media got attention for some valuable foods and health-enhancing 
effects of using shiitake mushroom and beneficial bacteria (Vargas & Ohashi, 1996). Shiitake 
mushroom (Lentinus edodes (Berk.) Singer) extract contains many oligosaccharides and 
polysaccharides (Kawakami et al., 2004), and is considered a prebiotic. Probiotics growth is 
stimulated by oligosaccharides and polysaccharides similar to those found in mushrooms 
(Vargas & Ohashi, 1996). Shiitake mushroom popular for its edible and medicinal mushroom 
has become the 2nd most cultivated mushrooms in the world (Chang, 1993). Shiitake mushroom 
contains antitumor polysaccharides (Guo et al., 2004). Most clinical evidence for antitumor 
                                                 
1
 Parts of this chapter were adapted from: Hassan, O.A., Ibrahim S.A., Song D., Isikhuemhen, O., Shahbazi, 
A. & AbuGhazaleh A.A. Milchwissenschaft, 66(3) (2011). 
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activity comes from polysaccharides lentinan (Wasser, 2002). Many studies showed that 
polysaccharides from mushrooms do not attack cancer cells directly, but produce their antitumor 
effects by activating different immune responses in the host (Guo et al., 2004). In this study we 
investigate the effect of shiitake mushroom extract on the growth of bifidobacteria and 
lactobacilli in vitro.  
3.2. Materials and Methods 
3.2.1. Preparation of shiitake mushroom. Fresh shiitake mushroom was obtained from 
a local market in Greensboro, North Carolina. The mushroom was dried under a freeze drying 
machine (Labconco Freeze dryer, Kansas city, Mo, USA), powdered, and then sieved (particle 
size 1 mm). Mushroom extract (1%, 2%, and 4%) was heated on hot plates at 80°C for three 
hours (Minato, Mizuno, Terai, & Tsuchida, 1999). After cooling to room temperature, mushroom 
extract was filtered twice first through Whatman number 1 filter paper (Whatman Corp., Clifton, 
NJ, USA), and then through Nalgene filter unit with 0.2 um pore size (Nalge Nunc International, 
Rochester, NY, USA). The extract was then stored in a freezer at -20°C.  
 3.2.2. Chemical analysis of shiitake mushroom. 
 3.2.2.1. Proximate analysis of mushroom. Proximate chemical composition of 
mushroom sample powder, including moisture, ash, protein, and lipid were determined according 
to the Association of Official Analytical Chemists methods (AOAC, 1995). Carbohydrate 
content on a dry weight basis was calculated by following the formula: % carbohydrate = 100% - 
% ash - % protein - % lipid (on a dry matter basis). 
3.2.2.2. High performance liquid chromatography (HPLC) analysis. One milliliter of 
shiitake mushroom extract was taken for sugars analysis. Samples were extracted with hot water 
(85ºC) for three hours. Samples were prepared for HPLC filtered by micro-filter (0.45 µm). The 
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samples were applied to a shodex KC-811 fermentation column (Water corp., Milford, MA, 
USA), a column (8x 300mm) used in conjunction with a Waters 410 differential refractive index 
detector for identification specific carbohydrate. The mobile phase was 0.1% H3PO4 at a flow 
rate of 1 mL/min. 
3.2.3. Media preparation. Fifty-five grams of MRS (de Man Rogosa Sharpe broth) from 
Difco Laboratories (Becton Dickinson, Sparks, MD) was dispensed in 1 L of deionized water 
and allowed to stir moderately for 10 min to allow media to dissolve. Cysteine-hydrochloride 
(0.5 g/L) was added as the reducing agent and allowed to stir at low speed (5-10 rpm) for an 
additional 10 min to dissolve (Poch & Bezkorovainy, 1991). 
3.2.4. Culture conditions. Four strains of Lactobacillus and Bifidobacterium sp. 
obtained from the culture collection in the Food Microbiology Laboratory at North Carolina 
A&T State University were tested in this study (Table 3.1). All strains were maintained on 
Lactobacillus MRS agar Petri dishes at 4ºC. Before use, the strains were activated by taking one 
bacterial colony of each strain and separately inoculated the colony into Lactobacillus MRS 
broth in anaerobic culture tubes at 37°C for 18 hour. 
Table 3.1 
Probiotics strains that were used in this project  
Strains Original sources 
Lactobacillus reuteri DSM20016 Mother‟s milk 
Lactobacillus reuteri CF2-7F Child fecal isolate 
Bifidobacteria breve ATCC 15701 Infant stools 
Bifidobacteria adolescentis ATCC 15704 Human feces 
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3.2.5. Sample preparation and treatment. Batches of MRS broth containing different 
concentrations of shiitake mushroom extract were prepared. Bacterial strains were inoculated 
into individual test tubes with MRS medium and shiitake mushroom extract at different 
concentrations (0, 1, 2, and 4% w/v) and incubated at 37ºC for 8 hr. 
 3.2.6. Bacterial growth. Bacterial growth was monitored by measuring optical density 
(O.D. 610 nm) at different time intervals (0, 2, 4, 6, and 8 hours) using a spectronic 21 Milton 
Roy spectrophotometer (Model Genesys 10 Vis, Thermospectronic, Rochester, NY, USA).  
3.2.7. Bacterial enumeration. Bacterial populations were determined by plating onto 
MRS agar plates. Samples (1mL) were withdrawn from inoculated samples at 8 hours, serially 
diluted in 1% peptone water, and then appropriate dilutions were surface plated (100 µL) onto 
duplicate plates of MRS agar. Colonies were counted after incubation at 37C for 72 h to 
determine bacterial population. 
 3.2.8. Determination of pH and titratable acidity. Samples were withdrawn at 
different time intervals (0, 2, 4, 6, and 8 hours) to measure pH values. The pH meter (model 
410A, Orion, Boston, MA) was calibrated with pH standard buffers 4.0 and 7.0. After 
calibration, sample pH was taken and recorded. Between different samples, electrode was rinsed 
with distilled water. The titratable acidity was determined after mixing the 1 mL of sample with 
9 mL of distilled water by titrating with 0.1 N NaOH to the pH 8.6 using a pH meter (model 
410A; Orion, Boston, MA) and titrator (Dejardins & Roy 1990). 
3.2.9. Statistical analysis. Data analyses were focused on determining if the addition of 
shiitake mushroom extract resulted in significantly greater growth over that of the control 
samples. Statistical analysis of data was performed using the SAS General Linear Model (GLM) 
program (1999). Duncan‟s Multiple Range Test was used to determine significant (P < 0.05) 
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differences. For each growth condition, triplicate samples were tested for the growth of all 
strains. 
3.3. Results and Discussion 
 3.3.1. Composition of shiitake mushroom. Table 3.2 shows the chemical composition 
of the shiitake mushroom extract. Shiitake mushroom extract contained 22% dry matter, 6.66% 
ash, 60% carbohydrate, 29.06% protein, and 1.5% lipid (dry matter basis). According to analysis 
by HPLC, shiitake mushroom extract contains 0.033% raffinose, 0.035% glucose, 0.045% 
trehalose and 0.069% arabinose (Figure 3.1). The large portion of protein content could be in the 
form of amino acids, small peptides and nucleic acids material (Vargas & Ohashi, 1996). 
Table 3.2 
Chemical composition of shiitake mushroom 
 
 
 
Figure 3.1. Simple sugars in shiitake mushroom extract 
Content g/100 g DM weight 
Ash 
Protein 
Carbohydrate 
Lipid 
pH 
6.66 
29.06 
54.00 
1.5 
5.59 
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3.3.2. Change in pH value. The results provided in Figure 3.2 are the mean triplicate pH 
measurements for shiitake mushroom extract samples. Figure 3.2 shows the acid production of 
each strain in combination with shiitake mushroom extract. As time increased there was an 
increase in the amount of acid produced in all strains causing a decrease in pH. Strains 
supplemented with the appropriate concentration of shiitake mushroom extract (4%) had the 
highest amounts of acid production after 8 hour. Strains supplemented with 1 or without SME 
had minimal acid production in comparison to the 2 and 4% of concentration of mushroom 
extract used in this study. 
 
Figure 3.2. Stimulatory effect of shiitake mushroom extract on pH variation in MRS culture 
media after 8 hour incubation 
The strains that produced more acid were L. reuteri DSM20016 and L. reuteri CF2-7F 
and B. adolescentis. B. breve had lower amount of acid production when supplemented with 
mushroom extract. The data showed over time intervals strains L. reuteri DSM20016 and L. 
reuteri CF2-7F had higher amounts of acid production versus control samples not supplemented 
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with mushroom extract. Lactic acid bacteria contain specific enzymes that are able to hydrolyze 
sugars. The continuous fermentation activity of lactic acid bacteria gradually produced more acid 
in the medium. 
3.3.3. Titratable acidity. During initial period there were minimal amounts of acid 
production. As time of incubation increased, there was an increase in the amount of acid 
produced in all strains. Strains supplemented with 4% of mushroom extract had higher amounts 
of acid production, while strains supplemented with 1 and 0% of mushroom extract had minimal 
acid production (P<0.001) (Figure 3.3). 
 
Figure 3.3. Stimulatory effect of shiitake mushroom extract on lactic acid production in MRS 
culture media after 8 hours incubation 
3.3.4. Bacterial enumeration. The growth rate of all strains used was enhanced with an 
increase in the concentration of mushroom extraction in MRS broth samples (P<0.001). Addition 
of mushroom extract at 2 and 4% were most effective in enhancing growth of all four strains 
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used in this study compared to control sample (without mushroom extract). The highest 
concentration (4%) of mushroom extract was the most effective on stimulate the growth of 
bifidobacteria and Lactobacilli (Table 3.3). The effect of shiitake mushroom extract on the 
growth rate of both Bifidobacterium (adolescentis and breve) and Lactobacillus retueri 
(DSM20016 and CF2-7F) was dependent on strain used and concentration of shiitake mushroom 
extract in the growth medium. 
Table 3.3 
Bacterial counts (log cfu/ml) of L. reuteri and Bifidobacterium spp grown in MRS culture media 
with different shiitake extract concentrations 
MRS + shiitake 
extract B. breve 
B. 
adolescentis L. reuteri CF-2F 
L. reuteri 
DSM20016 
0% 8.70
a
 7.63
a
 8.90
a
 8.23
a
 
1% 8.88
a
 7.74
b
 9.00
b
 8.36
b
 
2% 8.94
b
 7.79
b
 9.08
b
 8.37
b
 
4% 8.99
c
 7.83
c
 9.13
c
 8.43
c
 
abcd 
Means with different superscripts in the same column indicate significant differences (P<0.05) 
 
3.4. Conclusions 
Our results indicated that shiitake mushroom extract could enhance the growth of lactic 
acid bacteria and bifidobacteria. The growth rate of all strains used was improved with an 
increase in concentration of SME in MRS broth. The strains that produced high population after 
8 h of incubation at 37°C were L. reuteri CF2-7F, B.breve  and L. reuteri DSM20016 (9.13, 8.99 
and 8.43 log CFU/ml respectively). This may suggest the potential use of shiitake mushroom as a 
functional food product to promote the growth of probiotic strains in the human intestinal tract. 
Further research is needed to test efficacy in combination of shiitake mushroom extract with 
probiotic bacteria as a dietary supplement.  
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CHAPTER 4
1
 
Growth and Viability of Lactobacillus reuteri and Bifidobacterium in Skim Milk in the 
Presence of Shiitake Mushroom Extract during Refrigerated Period 
4.1. Introduction 
Lactic acid bacteria and bifidobacteria have been used as a functional food for human 
consumption with the purpose of enhancing human health. These bacteria called probiotics, 
defined as living organisms, when used in certain amounts, confer health benefits to the host 
(FAO, 2001). Dairy products are commonly used as a vehicle to carry probiotic bacteria. 
Recently, a number of research work showed significant health effects due to regular 
consumption of bacterial cultures, including lactic acid bacteria (Fonden, Mogensen, Tanaka, & 
Salminen, 2000). Therefore, due to the health promoting effects of lactic acid bacteria, there is an 
increasing interest in incorporating lactic acid bacteria and probiotics into milk and milk 
products (Broekart & Walker, 2006). The growth and viability of lactic acid bacteria are key 
factors required for developing probiotics in milk. The amount of bacterial cells required to 
produce a functional food is not well known and might vary as a characteristic of the strain and 
the health effect desired. A minimum level of more than 10
6
 viable probiotic bacteria per gram of 
food product is accepted (Ouweh & Salminen, 1998). Lactic acid bacteria are fastidious 
organisms and regular certain growth factors. In previous studies, investigators examined various 
supplements that stimulated the growth of lactic acid bacteria in artificial media and cow‟s milk 
(Poch & Bezkorovainy, 1988; Ibrahim & Bezkorovvainty, 1994; Rada, 1997; Farnworth, 
Mainville, Desjardins, Gardner, & Champagne, 2006). Prebiotics are defined as non-digestible 
food ingredients that beneficially affect the host by selectively stimulating the growth and/or 
                                                 
1
 Parts of this chapter were adapted from: Hassan, O.A., Ibrahim S.A., Song D., Isikhuemhen, O., Shahbazi, 
A., & AbuGhazaleh, A.A. International Probiotics and Prebiotics (2011). ( submitted). 
 
46 
 
 
 
activity of one or a limited number of bacteria in the colon and improve host health (Gibson & 
Roberfroid, 1995). The production of lactic acid allows efficient metabolism in the gastric 
environment of the gut, which contains high levels of acidic bile and pancreatic enzymes (Parvez 
et al., 2006; Camilleri, 2006). 
 Recently, there has been more concern on a combination of prebiotics and probiotics in 
many dairy products (Hammes & Hertel, 2002). Using shiitake mushroom and beneficial 
bacteria for some valuable foods and health enhancing effects is a very unique idea of Varagas 
and Ohash (1996). Shiitake mushroom (Lentinus edodes (Berk.) Singer) extracts contain mono 
and polysaccharides (Kawakami et al., 2004), and is considered as a prebiotic (Wasser, 2002; 
Guo, 2004). Probiotics growth is stimulated by oligosaccharides and polysaccharides similar to 
those found in mushrooms (Varagas & Ohashi, 1996). In this study, we investigated the effect of 
shiitake mushroom extract on the viability and survival of bifidobacteria and lactobacilli in skim 
milk during refrigerating storage.  
4.2. Materials and Methods 
4.2.1. Samples preparation and treatment. Skim milk was obtained from local market 
and sterilized at 116ºC for 10 min. To prepare each sample, 100 μL of shiitake mushroom extract 
at different concentrations (0, 1, 2, and 4%) active strains were added to skim milk (9.8 mL) 
previously inoculated (Table 3.1), and then kept at 4 ºC for four weeks (Alazzeh et al., 2009). 
Experiments were conducted to determine bacterial count, pH, and titratable acidity of the skim 
milk samples at one week intervals during storage at 4ºC for four weeks.  
4.2.2. Bacterial enumeration. Samples (1 mL) were withdrawn weekly for four weeks 
and serially diluted in 1% peptone water. Appropriate dilutions were surface plated onto MRS 
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agar plates. Bacterial colonies were counted after incubation at 37°C for 48 hrs to determine 
bacterial population. 
4.2.3. Determination of pH. The pH values were measured at one week intervals for up 
to 4 weeks. The pH meter (model 410A; Orion, Boston, MA) was calibrated with fresh pH 4.0 
and 7.0 standard buffers. The pH values of the samples were recorded and the electrode was 
rinsed with distilled water in between measurements of each sample. 
4.2.4. Lactic acid production. The amount of lactic acid production was determined 
after mixing the sample of appropriate concentration of shiitake mushroom and bacterium 
samples with 9 mL of distilled water. Samples were titrated with 0.1 N NaOH to the endpoint of 
pH 8.6 using a pH meter and titrator. The total of titratable acidity was expressed in term of 
lactic acid (%) according to the method used by Vargas & Ohashi (1996). 
4.2.5. Enzyme assay. 
4.2.5.1. α-Galactosidase assay. α-Galactosidase activity was assayed according to the 
Food Chemicals Codex (2003) protocol. α-Galactopyranoside activity was tested by adding 1 mL 
of p-nitrophenyl-α-D-galactopyranoside substrate to 0.5 mL of each sample and transfer all  the 
samples into  a shaker water bath at 37ºC for 15 minutes. All reactions were stopped by adding 
2.5 mL of borax buffer. A blank for each sample was prepared by sequentially adding 0.5 mL 
sample, 2.5 mL borax buffer and 1 mL of substrate solution. Spectrophotometer (Model Genesys 
10 Vis, Thermospectronic, Rochester, NY, USA) were used to measure absorbance at 405 nm.  
4.2.5.2. β-Galactosidase assay. β-Galactosidase activity was assayed according to the 
method described by Nagy et al. (2001). The reaction mixture composed of 0.5 mL of enzyme 
sample and 0.5 ml of 15 mM o-nitrophenyl-β-D-galactopyranoside in 0.03 M sodium phosphate 
buffer (pH 6.8) was maintained on a shaker water bath at 37
o
C for 10 minutes, and then 2.0 mL 
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of 0.1 M sodium carbonate were added to stop the reaction. The optical density for each of the 
samples was measured at 420 nm with spectrophotometer (Model Genesys 10Vis, 
Thermospectronic, Rochester, NY, USA). Units of activity are expressed as micro-moles of o-
nitrophenyl released per minute, 1U=1μmol/min (Hughes & Hoover, 1995). 
4.3. Results and Discussion 
4.3.1. Bacterial enumeration. At initial storage period, the mean bacterial population 
among skim milk samples ranged from 7.5 to 9.38 log cfu/ml among all strains used in this study 
(Figures 4.1-4.4). The bacterial count ranged between 6.7 to 9.35 log cfu/ml for all samples at 
the 7 day storage period, showing a significant decrease among samples treated without or 1%, 
and stable among others treated with 2 or 4%. Comparison between strains showed that B. 
adolescentis did not grow as fast as other strains (Figure 4.1). Examining the results of strains for 
different concentration of mushroom extract showed that there were minimal differences 
between mushroom extract affecting the survival and viability of lactic acid bacteria (Figures 
4.1-4.4). Adding mushroom extract at 2 and 4% concentration was most effective in enhancing 
the survival and viability of all the four strains used in this study compared to control samples. 
At the 28 day storage period, the bacterial population for 0, 1, 2, and 4% supplementation was 
7.20, 8.50, 8.82, and 9.15 log cfu/ml respectively when B. breve was used (Figure 4.1). The 
highest concentration (4%) of mushroom extract was the most effective in extending the viability 
of all strains (Figures 4.1, 4.2, 4.3 and 4.4). Results showed that energy source is an essential 
factor for the growth of bifidobacteria and L. reuteri strains. The growth and viability of lactic 
acid bacteria was enhanced with an increase in the concentration of prebiotics, such as 
mushroom extract (Hassan et al., 2011; Desai, Powell & Shah, 2004). 
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Error bars indicate standard deviation of triplicate samples. 
Figure 4.1. Viability of Bifidobacterium adolescentis grown in skim milk containing different 
concentrations of shiitake mushroom after 28 days of refrigerated storage at 4°C 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.2. Viability of Bifidobacterium breve grown in skim milk containing different 
concentrations of shiitake mushroom after 28 days of refrigerated storage at 4°C 
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Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.3. Viability of Lactobacillus reuteri CF2-7F grown in skim milk containing different 
concentrations of shiitake mushroom after 28 days of refrigerated storage at 4°C 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.4. Viability of Lactobacillus reuteri DSM 20016 grown in skim milk containing 
different concentrations of shiitake mushroom after 28 days of refrigerated storage at 4°C 
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In general, bifidobacteria and L. reuteri spp., grown on skim milk (without mushroom 
extract) reduced the survival and viability than those with mushroom extract (P<0.001).The 
effect of shiitake mushroom extract on the survival and viability of both B. (adolescentis and 
breve) and L. reuteri (DSM20016 and CF2-7F) was dependent on the strain used and the 
concentration of shiitake mushroom extract added to the storage medium. However, the viability 
and survival were significantly higher (P<0.05) than that of control, when no prebiotics were 
used, which could be attributed to enriched carbon, nitrogen and other mineral in the samples 
with mushroom extract. 
4.3.2. Determination of pH. In this study the growth and acid production of L. reuteri 
strains and Bifidobacterium spp. were measured. Readings were taken over 28 days at 7 days 
intervals (0, 7, 14, 21, and 28 days). During the initial incubation periods of 0 and 7 days there 
was drop in pH ranging from 6.51-6.3 (Figures 4.5-4.8). As time increased, there was an increase 
in the amount of acid produced in each L reuteri and Bifidobacterium strains. Samples 
containing the appropriate amount of mushroom extract showed high amounts of acid production 
over time, while in contrast, control samples that contained no mushroom extract showed 
minimal acid. Mushroom extract concentration at 2 and 4% yielded high amounts of acid 
production, while 0 and 1% had minimal acid production in comparison to other concentrations 
used in this study (Figures 4.5, 4.6, 4.7, and 4.8). The most prevalent amount of acid production 
was observed in strain L. reuteri CF2-7F and DSM 20016 (Figures 4.5 and 4.6). B. breve and 
adolescentis were sensitive to acid production in the presence of mushroom extract (Figures 4.7 
and 4.8). The results provided in Figures 4.5, 4.6, 4.7 and 4.8 are the mean of triplicate pH 
measurements for mushroom extract with skim milk samples. As indicated in these figures, milk 
with different prebiotic concentrations required different fermentation times to reach lowered 
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pH. Data displayed in Figures 4.5, 4.6, 4.7 and 4.8 showed that over time all strains produced 
higher amounts of acid when supplemented with mushroom extract versus control samples, and 
this dropped pH to the range of 5.0-5.13. Although there was high amount of growth observed, 
statistical analysis showed that there was a statistically significant difference in acid production 
of L. reuteri (P<0.05). L. reuteri DSM 20016 showed a significant difference in acid production 
between control samples and those containing mushroom extracts. 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.5. pH change in skim milk with Lactobacillus reuteri CF2-7F and different 
concentrations of shiitake mushroom extracts stored at 4ºC during 28 days 
4.3.3. Titratable acidity. The analytical study measured the percentage of lactic acid 
production of L. reuteri and bifidobacteria by titratable acidity. Figures 4.9-4.12 shows the acid 
production rankings for L. reuteri spp. and Bifidobacterium spp. used in this study by measuring 
the total percentage of lactic acid. 
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Error bars indicate standard deviation of triplicate samples. 
Figure 4.6. pH change in skim milk with Lactobacillus reuteri DSM 20016 and different 
concentrations of shiitake mushroom extracts stored at 4ºC during 28 days 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.7. pH change in skim milk with Bifidobacterium breve and different concentrations of 
shiitake mushroom extracts stored at 4ºC during 28 days 
 
54 
 
 
 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.8. pH change in skim milk with Bifidobacterium adolescentis and different 
concentrations of shiitake mushroom extracts stored at 4ºC during 28 days 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.9. Stimulatory effect of shiitake mushroom extract on lactic acid production by 
Bifidobacterium breve in skim milk after 28 days stored at 4ºC 
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Error bars indicate standard deviation of triplicate samples. 
Figure 4.10. Stimulatory effect of shiitake mushroom extract on lactic acid production by 
Bifidobacterium adolescentis in skim milk after 28 days stored at 4ºC 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.11. Stimulatory effect of shiitake mushroom extract on lactic acid production by 
Lactobacillus reuteri CF2-7F in skim milk after 28 days stored at 4ºC 
56 
 
 
 
 
Error bars indicate standard deviation of triplicate samples. 
Figure 4.12. Stimulatory effect of shiitake mushroom extract on lactic acid production by 
Lactobacillus reuteri DSM 20016 in skim milk after 28 days stored at 4ºC 
Readings of titratable acidity were taken over 28 days at five 7 days intervals. During the 
initial time intervals, there was minimal amount of lactic acid production. As storage time 
increased, there was an increase in the amount of lactic acid produced in each L. reuteri spps and 
Bifidobacterium spp. Samples supplemented with shiitake mushroom extract (2 and 4%) had 
high amounts of lactic acid production ranging from 0.24-34% by the end of 28 days, while 
strains supplemented with the 0 and 1% had minimal acid production of 0.14-27% (see Figures 
4.9-4.12). 
 The strains that produced the most lactic acid were DSM 20016 and CF2-7F. 
Bifidobacterium breve and adolescentis had low amounts of acid production when supplemented 
with shiitake mushroom extract. The data showed that over time, strains DSM 20016 and CF2-
7F produced higher amounts of lactic acid versus control samples not supplemented with 
mushroom extract.  
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There were high amounts of growth observed, and statistical analysis showed a 
significant statistical difference in acid production of L. reuteri strains (P<0.05) than 
Bifidobacterium spps. L. reuteri DSM 20016 showed a significant difference in acid production 
between samples supplemented with mushroom extract and the control (P<0.05), (Figures 4.9-
4.12). In addition, data showed that there was a statistically significant difference between 
strains. All strains supplemented with mushroom extract had generated more lactic acid 
production than control (P<0.01). Strains supplemented with 2 and 4% of shiitake mushroom 
extract observed high levels of acid production whereas strains supplemented with 0 and 1% of 
mushroom extract  had less acid production in comparison to other concentrations (see Figures 
4.9-4.12).  
Generally, in this study the survival of probiotics was improved by the addition of 
mushroom extract to skim milk. This study agrees with the previous investigation that indicated 
shiitake mushroom extract has improved the bioavailability of minerals such as calcium, 
magnesium and iron and they increase the absorption of calcium and magnesium in the large 
intestine (Frank, 2000; Scholz-Ahrens, Schaafsma, Vanden Heuvel, E. G. & Schrezenme, 2001). 
Use of polysaccharides and monosaccharide in the diet on daily basis produce substantial 
changes in the intestinal microflora and increase the faecal bifidobacteria count and reduce the 
potential pathogens such as Clostridium, E. coli (Gibson & Roberfroid, 1995). 
4.3.4. Enzyme activity. β-Galactosidase and α-galactosidase activities varied 
considerably among the strains used in this study. The magnitude of the differences in the 
enzyme activity, between Bifidobacterium and Lactobacillus, was varied. Bifidobacteria 
exhibited unique characteristics in its growth in skim milk with mushroom extract. β-
Galactosidase and α-galactosidase activities were detected in all strains. β-Galactosidase activity 
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of Bifidobacterium spp., was much greater than that of Lactobacillus spp. During refrigerated 
storage, there was a significant reduction in enzyme activity of all strains depending on the 
amount of mushroom extract added to the sample. Samples treated with 2 and 4% of mushroom 
extract showed higher amount of enzyme activity and stability during incubated time at 4ºC.  
4.3.4.1. α-Galactosidase assay. Results showed that L. reuteri strains DSM20016 and B. 
adolescentis (1.8 and 1.6, Gal U/ml, respectively) (Table 4.1) had a significantly higher (P < 
0.05) α-galactosidase activity than Bifidobacteria breve and L. reuteri CF2-7F (1.3 and 1.25 Gal 
U/ml, respectively) on the first week when 4% of shiitake mushroom extract was used. 
Generally, all strains used in this study showed stability and significant production of α-
galactosidase activity until the fourth-week when 2 and 4% of shiitake extract was used. 
Table 4.1 
The effect of mushroom extract on α-galactosidase activity by Bifidobacterium spp and 
Lactobacillus reuteri during storage at 4ºC for 28 days 
Shiitake 
Extract 
  
day 7 
  
day 28 
  
DSM CF2 B. breve 
B. 
adolescentis DSM CF2 B. breve 
B. 
adolescentis 
0% 0.48±.03 0.66±.03 0.84±.01 0.51±.03 0.24±.03 0.48±.01 0.51±.05 0.24±.01 
1% 0.57±.12 0.69±.03 0.90±.01 0.63±.03 0.38±.01 0.57±.06 0.87±.01 0.33±.05 
2% 1.32±.07 0.94±.02 1.10±.03 1.14±.10 1.25±.02 0.96±.01 1.20±.01 1.05±.12 
4% 1.79±.13 1.31±.07 1.24±.17 1.64±.25 1.57±.12 1.27±.01 1.30±.01 1.49±.10 
 
Figures 4.13-4.16 show α-galactosidase activity production of each strain in combination 
with shiitake mushroom extract. On the first week of storage at 4ºC, as time increased, there was 
stability in the amount of α-galactosidase activity in all strains when supplemented with the 
appropriate concentration of shiitake mushroom extract. The highest amount of α-galactosidase  
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activity was observed on 28
th
 day when 4% of mushroom extract (1.57 Gal U/ml) was used. 
Strains supplemented with 0 or 1% of mushroom extract had minimal α-galactosidase activity 
(0.24 and 0.33 Gal U/ml respectively) in comparison to the 2 and 4% concentration used in this 
study.  
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.13. α-Galactosidase activity (Gal U/ml) of L. reuteri DSM 20016 in skim milk 
containing different concentrations of shiitake mushroom extract 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.14. α-Galactosidase activity (Gal U/ml) of Bifidobacterium breve in skim milk 
containing different concentrations of shiitake mushroom extract 
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Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.15.  α-Galactosidase activity (Gal U/ml) of Lactobacillus reuteri CF2-7F in skim milk 
containing different concentrations of shiitake mushroom extract 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.16. α-Galactosidase activity (Gal U/ml) of Bifidobacterium adolescentis in skim milk 
containing different concentrations of shiitake mushroom extract 
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Our results and that of Alazzeh et al. (2009) are comparable. Alazzeh et al. (2009) found 
that the α-galactosidase activity of Lactobacillus reuteri was in the range of 0.92-10.55 Gal U/ml 
with the highest enzymatic activity when different carbohydrates sources were used. Garro et al. 
(2004) also reported that raffinose in a high pH environment leads to an increase of α-
galactosidase activity in Bifidobacterium longum. This was expected since α-galactosidase 
hydrolyzes the α-galactoside bonds in oligosaccharides such as raffinose. Shiitake extract rich in 
carbohydrate, such as arabinose, glucose, trehalose and raffinose (Hassan et al., 2011). 
4.3.4.2. β-Galactosidase assay. L. reuteri strains had generally higher β-galactosidase 
activity than bifidobacteria (see Table 4.2 and Figures 4.17-4.20). DSM20016 and CF2-7F had 
significantly higher (P < 0.05) β-galactosidase activity (5.39 and 4.8 Gal U/ml, respectively), 
than B. breve and B. adolescentis (4.36 and 3.7 Gal U/ml, respectively).  
Table 4.2 
The effect of mushroom extract on β-galactosidase activity by Bifidobacterium spp and 
Lactobacillus reuteri during storage at 4ºC for 28 days  
Shiitae 
Extract 
  
day 7 
   
day 28 
  
DSM CF2 B. breve 
B. 
adolescentis   DSM CF2 B. breve 
B. 
adolescentis 
0% 1.04±.12 0.79±.0 2.22±.05 1.91±.06 
 
0.80±.02 0.56±.06 1.70±.11 1.72±.15 
1% 1.46±.04 0.93±.17 2.39±.0 2.18±.04 
 
1.47±.06 0.77±.02 2.12±.03 1.93±.04 
2% 2.38±.04 3.84±.18 3.30±.02 2.87±.07 
 
2.30±.07 3.54±.2 3.20±.13 2.77±.08 
4% 5.29±.01 4.8±.22 4.15±.04 3.82±.15 
 
5.06±.15 4.93±.03 4.06±.13 3.73±.17 
 
Several studies have investigated the possibility of increasing the activity of α- and β-
galactosidases in different bacterial strains. Dumortier, Brassart, and Bouquelet (1994), observed 
that β-galactosidase activity of B. bifidum occurred at higher temperature. Others got it back to 
the differences in cell mass, cell growth, or variable number of cell per gram of culture (Occhino, 
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Morris & Savaiano, 1986; Hsu, Yu & Chou, 2005). Hsu et al. (2005) indicated that carbohydrate 
and nitrogen source, pH of the media, and mineral additive have a significant effect on 
increasing the β-galactosidase activity in bifidobacteria. 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.17. β-Galactosidase activity (Gal U/ml) of Lactoacillus reuteri DSM 20016 in skim 
milk containing different concentrations of shiitake mushroom extract 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.18. β-Galactosidase activity (Gal U/ml) of Bifidobacterium breve in skim milk 
containing different concentrations of shiitake mushroom extract 
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Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.19. β-Galactosidase activity (Gal U/ml) of Lactobacillus reuteri CF2-7F in skim milk 
containing different concentrations of shiitake mushroom extract 
 
Error bars indicate standard deviation of triplicate samples. 
 
Figure 4.20. β-Galactosidase activity (Gal U/ml) of Bifidobacterium adolescentis in skim milk 
containing different concentrations of shiitake mushroom extract 
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The high α-galactosidase enzymatic activity of L. reuteri DSM20016 and B. adolescentis 
and the high β-galactosidsase activity DSM20016 and CF2-7F are promising and the conditions 
for growing these bacteria to obtain hyper productivity levels of these enzymes could be further 
investigated. 
4.4. Conclusions 
 Adding SME at 2 and 4% to skim milk was most effective in enhancing the viability of 
all strains used in this study during 28 days of storage period at 4°C. Generally bifidobacteria 
and L. reuteri strains grown on skim milk without SME reduced the survival and viability than 
those with SME (P<0.001). The result showed that over time all strains produced higher amounts 
of acid when supplemented with SME compared to control samples, and this dropped pH to the 
range of 5.0 to 5.13. The strains that produced the most lactic acid were L. reuteri DSM20016 
and CF2-7F whereas Bifidobacterium breve and adolescentis had low amounts of acid 
production when supplemented with SME. 
L. reuteri DSM 20016 and B. adolescentis gave best α galactosidase activity when treated 
with 4% SME at 7 days (1.8 and 1.6 Gal U/ml, respectively) had significantly higher (P<0.05) 
than Bifidobacterium breve and L. reuteri CF2-7F (1.3 and 1.25 Gal U/ml, respectively). 
L.reuteri strains had generally higher β-galactosidase activity than Bifidobacterium spp. The 
results showed that L. reuteri strains grown in skim milk supplemented with SME provid good 
condition as good probiotic bacteri. This may suggest the potential use of shiitake mushroom as a 
functional food product to promote the growth of probiotic strains in the intestinal tract. 
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CHAPTER 5
1
 
Viability and α/β-Galactosidase Activities of Bifidobacterium Breve and Lactobacillus 
Reuteri DSM 20016 in Yogurt Products Supplemented by Shiitake Mushroom Extract 
during Refrigerated Storage 
5.1. Introduction 
The human gut contains over 500 different microbial species. The original 
microorganisms, which are the dominant microflora in the large intestine, reduce the ability of 
pathogenic genera including, Salmonella, Clostridium, Escherichia and Campylobacter to attach 
to the intestinal surface (Ziemer & Gibson, 1998). When the microbial balance is disturbed, 
intestinal bloating and diarrhea may occur. The popularity of probiotics has been increasing 
rapidly worldwide (Sanders, 2000; Sanders 2003; Rafter, 2004; Benkouider, 2004 (a, b); 
Kotilainen, Rajalahti, Ragasa, & Pehu, 2006). The probiotic genera of bifidobacteria and 
lactobacilli have been widely studied and established as valuable native inhabitants of the human 
intestinal tract. Probiotics are defined as live microbial feed supplements which beneficially 
affect the host by improving the intestinal microbial balance (Fuller, 1989). In the recent years, 
probiotics have caught the attention of the food industry (Saarela et al., 2002; Salminen & 
Gueimonde, 2004). Food industries are increasingly manufacturing different kinds of foods 
containing probiotic bacteria, which are called functional foods. Dairy products incorporated 
with probiotics such as yogurts containing L. acidophilus and Bifidobacterium spp. constitute a 
significant amount among the commercially available probiotic foods (Reid et al., 2003). 
However, in recent days, the increasing use of probiotic dairy products, especially probiotic 
yogurt, has attracted the market for probiotic yogurt and other foods where probiotics can be 
                                                 
1
 Parts of this chapter were adapted from: Hassan, O.A., Ibrahim S. A., Song D., Isikhuemhen, O. Shahbazi A., & 
AbuGhazaleh A. A. Journal of Dairy Science (2011). (To be submitted). 
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incorporated (Playne, 2002). Maintaining the growth and viability of probiotic bacteria in dairy 
products remains a major challenge to the fermented dairy producers because of the inability of 
many strains to grow well in milk. Therefore, there were many suggestions to use some nutrients 
to enhance the growth and survival of different probiotic strains. 
Considerably viable probiotic organisms reduce or eliminate sickness such as colon 
infection, irritation, constipation and traveler‟s diarrhea. Also, other health benefits include 
inhibition of pathogenic bacteria, lowering of blood pressure, synthesis of B vitamins, 
cholesterol absorption, high of ammonia levels, and inhibition of tumor formation (Roberfroid, 
2000; Ziemer & Gibson, 1998). However, in order to provide health benefits, it is essential that 
there is a minimum of 6 log cfu of viable probiotic organisms per gram of a product (Shah, 2002; 
IDF, 1992; Lourens, Viljoen, & Jooste, 2000; Lourens-Hattingh & Viljoen, 2001). Some reports 
have shown probiotic growth and survival numbers to be stable during the shelf life of the 
product (Dinakar & Mistry, 1994), others have cited a rapid decline in the number of viable 
probiotic bacteria over  shelf life (Ibrahim & Carr, 2005; Stanton, Desmond, Fitzgerald, & Ross,  
2003). Using prebiotic or hydrolyzed milk to improve the growth and survival of probiotic 
bacteria, especially bifidobacteria, the results showed a variety of effects depending on the strain 
and the dairy product used (Alkalın, Fenderya, & Akbulut, 2004). However, a limited number of 
studies have examined the effect of prebiotic on the growth and survival of Bifidobacterium spp.  
Ibrahim and Carr (2006) reported that in many commercial yogurt brands, probiotic 
organisms were not viable after 3-4 weeks of storage at 4ºC. It has been known that using 
mushroom extract help in maintaining the viability of probiotics. Also, using mushroom extract 
in dairy products could help to carry out natural substrates with probiotics to reduce cell losses 
during processing and storage at low temperature (Hassan et al., 2011a). 
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The survival of probiotics including L. bacillus returi and Bifidobacterium spp. was 
improved by the addition of mushroom extract at 4% w/v to skim milk (Hassan et al., 2011b). 
Therefore, there is a need to study the effect of shiitake mushroom extract a prebiotic, to improve 
the viability of probiotic organisms in yoghurt during refrigerated storage. Gibson and his team 
proved that prebiotics showed resistance to gastrointestinal infection because of their stimulatory 
effect on Bifidobacterium spp., by producing several anti- microbial mechanisms (Gibson et al., 
2005). Prebiotics can help to increase the beneficial bacteria in the gastrointestinal tract. Alazzeh 
et al. (2009) showed that Lactobacillus reuteri utilizes lactose, raffinose, and galactose besides 
glucose, and has the ability to metabolize oligosaccharides and the simple sugars. This ability is 
strain related, for example it has been found that Bifidobacterium spp and L. reuteri possessed 
the enzymes required to utilize some kind of sugar such as raffinose family and lactose 
(Martınez-Villaluenga & Gomez, 2007; Hassan et al., 2011b). A general increase in the 
beneficial bacterial population may not necessarily contribute to increased health effects, as it is 
strain related in this investigation, probiotic organisms were selected based on their ability to 
grow well and survive longer in yoghurt at 4ºC. The objective of this study was to investigate the 
effectiveness of mushroom extract, on the viability of Lactobacillus reuteri DSM20016 and 
Bifidobacterium breve after processing and storage of yoghurt for 35 days. 
5.2. Materials and Methods 
5.2.1. Production of freeze-dried starters. Four batches of de Man Rogosa Sharpe 
(MRS) broth were inoculated with each strain (Table 3.1) and were incubated for 24 h at 37°C. 
Samples were centrifuged at 8000 g for 15 min. Pellets were washed and re-suspended in 
peptone water to its original volume. The cells were inoculated at 5.0 log cfu/mL to skim milk 
and allowed to ferment overnight at 37°C. Yoghurt produced were transferred to the shell freezer 
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at −50°C for 2 h and lyophilized in a Labconco freeze-dryer at −55°C for 72 h under 0.040 Mbar 
pressure to produce freeze-dried starters. 
5.2.2. Mushroom substrate. Mushroom extract at different concentration 0% (control) 
and 4% were added into skim milk. The substrates were heated at 85ºC for 10 min and then 
cooled to 37ºC. 
5.2.3. Fermentation and storage. The mushroom substrate were inoculated with 5% 
(v/v) starter culture and incubated at 37ºC for 10 h. Yoghurt produced were stored at 4ºC for 5 
weeks. 
5.2.4. Viable cell enumeration. Enumeration of viable cells of Lactobacillus reuteri 
DSM 20016 and Bifidobacterium breve were performed through the estimation of colony 
forming unit on MRS agar plates after incubating at 37ºC for 48 h.  
5.2.5. Determination of Ph and titratable acidity. The pH meter (model 410A, Orion, 
Boston, MA) was used for the measurement of pH. Titratable acidity was determined by titrating 
10-mL samples with 0.1 N NaOH with an end point of pH 8.6 under constant stirring. Titratable 
acidity was recorded as the percentage equivalent of lactic acid.  
5.2.6. Enzyme assay.  
5.2.6.1. α-Galactosidase assay. α-Galactosidase activity was assayed according to the 
Food Chemicals Codex (2003) protocol. α-Galactopyranoside activity was tested by adding 1 mL 
of p-nitrophenyl-α-D-galactopyranoside substrate to 0.5 mL of each sample and transferring all  
the samples into  a shaker water bath at 37ºC for 15 minutes. All reactions were stopped by 
adding 2.5 mL of borax buffer. A blank for each sample was prepared by sequentially adding 0.5 
mL sample, 2.5 mL borax buffer and 1 mL of substrate solution. Spectrophotometer (Model 
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Genesys 10 Vis, Thermospectronic, Rochester, NY, USA) was used to measure absorbance at 
405 nm.  
5.2.6.2. β-Galactosidase assay. β-Galactosidase activity was assayed according to the 
method described by Nagy, Kiss, Szentirmai, & Biro (2001). The reaction mixture was 
composed of 0.5 mL of enzyme source and 0.5 ml of 15 mM o-nitrophenyl-β-D-
galactopyranoside in ml of 0.03 M sodium phosphate buffer (pH 6.8). Reactions were maintained 
on a shaker water bath at 37ºC for 10 minutes, and then 2.0 mL of 0.1 M sodium carbonate was 
added to stop the reaction. The optical density for each of the samples was measured at 420 nm 
with spectrophotometer (Model Genesys 10Vis, Thermospectronic, Rochester, NY, USA). Units 
of activity was expressed as micro-moles of o-nitrophenyl released per minute, 1U=1μmol/min 
(Hughes & Hoover, 1995). 
5.2.7 Statistical Analysis. Data analyses were concerned on determining if addition of 
shiitake mushroom to the yogurt products resulted in significantly affect the viability and 
enzymes activity of the control group. Statistical analysis of data was performed using the SAS 
General Linear Model program (1999). Least square means of triplicate samples were calculated 
and Duncan‟s multiple range test used to determined significant (P<0.01) differences.  
5.3. Results and Discussion  
5.3.1. Storage study. For the storage study yogurt samples processed using shiitake 
mushroom extract at different concentration levels (control, 1, 2, and 4%) were stored in the 
refrigerator at 4ºC and samples were pulled out at 0, 7, 14, 21, 28, and 35 d to determine the 
microbiological, and chemical quality. 
5.3.2. Determination of viability during refrigerating storage. Figures 5.1 and 5.2 
show the viability of Lactobacillus reuteri DSM 20016 and Bifidobacterium breve in yogurt 
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samples prepared using different concentration of shiitake mushroom extract (SME) during 5
th
 
week of storage at 4°C. At initial time of storage, the mean bacterial population among the 
yogurt samples ranged from 8.15-8.62 log CFU/ml (Table 5.1 and Figures 5.1-5.2). The bacterial 
samples population in all the samples ranged between 7.72-8.20 log cfu/ml at first week storage 
period, showing a significant decreased (P<0.05) from the initial time among samples without 
SME (control) compared to other samples with SME (Figures 5.1-5.2). The bacterial population 
at 2
nd
  and 3
rd
 week showed stability within strains in yogurts with 4% of SME and in the same 
time decreased in the population stored without SME (0.20-0.30 log cfu/ml) (see Figures 5.1-
5.2). 
 
Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.1. Viability of Lactobacillus reuteri DSM 20016 grown in yogurt containing 0 or 
4% concentrations of shiitake mushroom extract after 35 days of refrigerated storage at 4°C 
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Error bars were taken of three samples as standard deviation. 
 
Figure 5.2. Viability of Bifidobacterium breve grown in yogurt containing 0 or 4% 
concentrations of shiitake mushroom extract after 35 days of refrigerated storage at 4°C 
The bacterial population for all samples at 4
th
 weeks storage period, reduced 
subsequently. At 5
th
 week storage period, the bacterial population for control (no SME added) 
and 4% of SME for Bifidobacterium breve and Lactobacillus reuteri DSM 20016 was 7.37, 7.95, 
7.40 and 8.00 log CFU/ml respectively compared to their initial bacterial population of 8.23, 
8.31, 8.24 and 8.33 log cfu/ml (Table 5.1). 
Table 5.1 
Determination of pH of Lactobacillus reuteri DSM 20016 and Bifidobacterium breve growth in 
yogurt with 0 and 4% of SME over 35 days refrigerated storage at 4ºC. 
pH value 
Lactobacillus reuteri DSM 20016 Bifidobacterium breve 
Shiitake mushroom extract Shiitake mushroom extract 
0% 4% 0% 4% 
Initial 4.29±0.03 4.21±.02 4.39±.03 4.23±.03 
Final 4.01±0.01 3.6±0.1 4.0±.03 3.6±.03 
Note. Samples were taken in triplicate. 
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Generally, the bacterial population at 5
th
 week storage period when compared to initial 
time, showed a significant decreased (P<0.05) in the control samples, while samples with 4% of 
SME showed stability in strains viability when stored at 4°C. The results suggested that prebiotic 
especially 4% SME in yogurt can stimulate the viability of L. reuteri DSM 20016 and B. breve in 
the fermented products and possibly in the gastrointestinal tract. The results indicated that the 
addition of 4% concentration of SME showed growth promoting effect of Bifidobacterium spp. 
and Lactobacillus reuteri strains in pasteurized skim milk compared to control (containing no 
prebiotics). Shin et al. (2000) and Akalin et al. (2004) indicated similar results where a maximum 
effect was observed when they used 5% of FOS or Inulin. This research indicated that growth, 
survival and activity of L. reuteri spp and B. breve at 4% concentration of SME in skim milk was 
beneficial, and these strains improved in the presence of SME compared to the control without 
prebiotics.  
5.3.3. Change in pH of yogurt. Table 5.2 shows the initial pH and pH values after 35 
days of storage. Figures 5.3 and 5.4 show the pH change over the period of fermentation for skim 
milk containing shiitake mushroom extract (SME) and in pasteurized skim milk cultured with 
Lactobacillus reuteri DSM 20016 and Bifidobacterium breve. The fermentation was carried 
under anaerobic conditions at 42ºC for all samples for 10 h, and then transferred to the 
refrigerator at 4ºC for 35 days. The results provided in Table 5.2 and Figures 5.3 and 5.4 are the 
mean of the triplicate pH measurements for SME samples. As indicated in Table 2, the samples 
with different prebiotic concentrations required different fermentation times. Data displayed in 
Figures 5.3 and 5.4 show the pH change over the fermentation period. As displayed in Figures 
5.3 and 5.4, in the absence of SME, the decrease of in pH indicated an increase in bacterial 
growth and reached its maximum in about 35 days. For successful growth, bacteria require 
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appropriate sources of carbon, nitrogen and sulfur together with certain inorganic ions (Forrest & 
Walker, 1971; Payne, 1976). 
Table 5.2 shows that the fermentation period decreased by increase in the concentration 
of the SME in the skim milk. The greatest effect was observed with the 4% SME in skim milk as 
it reached the lower pH in 35 days which decreased significantly (P<0.05) as compared to the 
control. 
Table 5.2 
 
Population of Lactobacillus reuteri DSM 20016 and Bifidobacterium breve grown in yogurt with 
0 and 4% of SME over 35 days refrigerated storage at 4ºC 
pH value Lactobacillus reuteri DSM 20016 Bifidobacterium breve 
Shiitake mushroom extract Shiitake mushroom extract 
0% 4% 0% 4% 
Initial  8.24±0.02 8.33±.01 8.23±.0 8.31±.01 
Final 7.4±0.05 8.0±0.03 7.37±.01 7.95±.05 
Note. Samples were taken in triplicate. 
 
 
Figure 5.3. The pH change of Lactobacillus reuteri DSM 20016 in yogurt with different 
concentrations of shiitake mushroom extract stored at 4ºC during 35 days 
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Error bars were taken of three samples as standard deviation. 
 
Figure 5.4. The pH change of Bifidobacterium breve in skim yogurt with different 
concentrations of shiitake mushroom extract stored at 4ºC during 35 days 
5.3.4. Titratable acidity. To study the effect of addition of shiitake mushroom extract on 
the bacterial growth of Lactobacillus reuteri and Bifidobacterium breve, a time course study of 
acid production was conducted at 42ºC in skim milk culture media for 10 h, with and without the 
addition of the mushroom extract, then the samples were transferred to the refrigerator at 4ºC for 
35 days. According to Smith, Hillier, and Lees (1975), acidity values can be used as a measure of 
the lactic acid bacteria growth in milk. Reading was taken over 35 days at intervals of 7 days.  
Samples containing 4% of SME showed a significant amount of lactic acid in both strains 
(1.75 and 1.40% respectively), while in contrast control samples that contained no SME had 
minimal amounts of lactic acid production (Figures 5.5 and 5.6). The largest amounts of lactic 
acid production were observed in strain L.reuteri DSM 20016. The statistical analysis showed 
that there was a significant difference in lactic acid production between L. reuteri DSM 20016 
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and B. breve (P<0.05) and also between samples containing SME and the samples containing no 
SME. This was well correlated with pH, by increasing the storage time.  
 
Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.5. Stimulatory effect of shiitake mushroom extract on lactic acid production of 
Lactobacillus reuteri DSM 20016 in yogurt after 35 days stored at 4ºC 
 
Error bars were taken of triplicate samples as standard deviation. 
Figure 5.6. Stimulatory effect of shiitake mushroom extract on lactic acid production of 
Bifidobacterium breve in yogurt after 35 days stored at 4ºC 
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5.3.5. Enzyme activity. Enzyme activities were measured by determining the rate of 
hydrolysis of p-nitrophenyl-α-D-galactopyranoside and ο-nitrophenyl-β-D-galactopyranoside, 
respectively. β and α -galactosidase activities varied considerably between the strains used in this 
study. The differences in the enzyme activity, among Bifidobacterium and Lactobacillus, were 
essential. Bifidobacteria exhibited unique characteristics in its survival in yogurt mixed with  
mushroom extract. β-Galactosidase and α-galactosidase activities were detected in all strains. β-
Galactosidase activity of Lactobacillus spp., was much greater than that of Bifidobacterium spp.  
During refrigerated storage, there was a significant reduction in enzyme activity of all strains 
depending on the amount of mushroom extract added to the sample. Samples treated with 4% of 
SME showed higher amount of enzyme activity and stability during incubating at 4ºC. 
5.3.5.1. α-Galactosidase assay. Results showed that L. reuteri strains DSM20016 grown 
in yogurt mixed with 4% of SME was higher than the control (5.0 and 3.0, Gal U/ml, 
respectively) (Figure 5.7). L. reuteri DSM 20016 exhibited significantly higher (P < 0.05) α-
galactosidase activity than Bifidobacterium breve since first week, when 4% of SME was used. 
L. reuteri DSM grown in yogurt without SME dropped on the first week and continued dropping 
until the end of the experiment (from 4.0 to 2.8 Gal U/ml). Refrigerated storage samples of L. 
reuteri DSM grown on yogurt with 0% of SME showed significantly reduced α-galactosidase 
activity ~1.2 Gal U/ml. However, the L. reuteri DSM samples grown on yogurt with 4% SME 
demonstrated stable α-galactosidase activity over 35 days period (Figure 5.7), at 4th week of 
storage at 4ºC, α-galactosidas activity decreased over time in samples without SME samples 
(Figure 5.7). Bifidobacterium breve in yogurt with and without SME had α-galactosidase activity 
in the range of (3.75 and 3.50 Gal U/ml respectively) at initial time (Figure 5.8). 
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Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.7. α-Galactosidase activity (Gal U/ml) of L. reuteri DSM 20016 in yogurt containing 0 
or 4% concentration of shiitake mushroom extract 
 
Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.8. α-Galactosidase activity (Gal U/ml) of Bifidobacteriu breve in yogurt containing 
0 or 4% concentration of shiitake mushroom extract 
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Generally, all strains used in this study showed stability and significant production of α-
galactosidase activity until the fifth-week when we used 4% of SME compared to the control. 
These results agree with Alazzeh et al. (2009)  when they found that α-galactosidase activity in 
L. reuteri (0.067-0.603 Gal U/ml) was higher than that produced by bifidobacteria (0.013-0.396 
Gal U/ml) and α-galactosidase activity of L. reuteri strains DSM20016 and MM2-3 was higher 
in comparison with the other bifidobacteria they investigated. Garro et al. (2006) also reported 
that raffinose in a high pH environment leads to an increase of α-galactosidase activity in B. 
longum. These results were expected since α-galactosidase hydrolyzes the α-galactoside bonds in 
monosaccharide such as raffinose. Shiitake extract rich in carbohydrate shows the highest peak 
for raffinose (Hassan et al., 2011). 
5.3.5.2. β-Galactosidase assay. L. reuteri strains had generally higher β-galactosidase 
activity than bifidobacteria (see Figures 5.9 and 5.10). β-Galactosidase activity obtained with 
DSM20016  grown in skim milk containing 4% of SME was significantly higher (P < 0.05) 
(6.75 Gal U/ml) than B. breve (5.10 Gal U/ml), after the 35 days. β-Galactosidase activity at the 
initial time of L. reuteri DSM 20016 on 0% and 4% of SME  were 5.0 and 7.6 Gal U/ml 
respectively. On the other hand, B. breve grown on skim milk in presence of SME at 0 and 4% 
concentration gave β-galactosidase activity of 3.3 and 5.2 Gal U/ml respectively after 35 days. 
 Many scientists have made many attempts to search the possibility of increasing the 
activity of α- and β-galactosidases in different bacterial strains by using various prebiotics. 
Dumortier et al. (1994), for example, observed that β-galactosidase activity of B. bifidum 
occurred at higher temperature. Others showed that of α- and β-galactosidases activity changes 
due to the differences in cell mass, cell growth, or variable number of cell per gram of culture 
(Occhino et al., 1986; Ramana & Dutta, 1981; Hsu et al., 2005). Hsu et al. (2005) said that 
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carbohydrate and nitrogen sources, pH of the media, and mineral additive have a significant 
effect on increasing the β-galactosidase activity in bifidobacteria. Also Ibrahim and O‟Sullivan 
(2000) showed that β-galactosidase activity increased the mutants of Bifidobacterium spp when 
they were exposed to chemical mutagenesis. 
 
Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.9. β-Galactosidase activity (Gal U/ml) of L. reuteri DSM 20016 in yogurt containing 0 
or 4% concentration of shiitake mushroom extract 
 
Error bars were taken of triplicate samples as standard deviation. 
 
Figure 5.10. β-Galactosidase activity (Gal U/ml) of Bifidobacteriu breve in yogurt containing 0 
or 4% concentration of shiitake mushroom extract. 
81 
 
 
 
5.4. Conclusion 
The viability of Lactobacillus reuteri DSM 20016 and Bifidobacterium breve in yogurt 
samples prepared using 4% SME during 35 days of storage at 4ºC compared to samples without 
SME showed stability in viability (7.9 to 7.8 log CFU/ml respectively). The results indicated that 
addition of 4% of SME to the samples showed growth prompting effect of L. reuteri DSM 20016 
and B. breve compared to samples without SME. The fermentation period reduced by increase of 
the concentration of SME in skim milk as it reached the lower pH in 35 days significantly 
(P<0.05) as compared to the control. After 35 days of storage at 4°C samples containg 4% SME 
showed asignificant amount of acid production in strain, L. reuteri DSM and B. breve (1.75 and 
1.40% respectively), while in contrast samples without SME had minimal amounts of acid 
production was observed in L. reuteri DSM. This may exert positive effect when shiitake 
mushroom used as a functional food product to promote the growth of probiotic strains in the 
human intestinal tract.       
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CHAPTER 6 
 
Conclusion and Future Directions 
The main purposes of the experiments describes in this dissertation were:  
a) To test the different effects of using a range of shiitake mushroom extract (SME) in 
different percentages, to determine the best concentration of this prebiotics on the growth 
of Lactobacillus reuteri and Bifidobacterium spp. When be added to MRS. 
b) To find the best shelf life of skim milk by SME on the growth and viability of 
Lactobacillus reuteri (DSM 20016 and CF2-7F) and Bifidobacterium spp (breve and 
adolescentis) 
c) To examine the effect of the prebiotics (SME) and the yogurt on the growth and viability 
of Lactobacillus reuteri DSM 20016 and Bifidobacterium breve and develop the best 
environments yogurt with exact concentrations of SME to have the highest growth and 
viability rate of Lactobacillus reuteri and Bifidobacterium spp. to validate their beneficial 
effect on growth and survival of other probiotic bacteria.  
This study clearly focused on the importance of the growth and viability of probiotics in dairy 
products. The use of prebiotics has been the focus of many studies over the last decades to 
enhance the growth and viability of probiotic bacteria. In conclusion this study was able to 
successfully find novel product and new method that give excellent and accurate CFU of 
probiotic bacteria. Therefore, this investigation successfully achieved its objectives by adding 
4% of SME on MRS media, skim milk and yogurt. In the future more research should be held 
using more techniques to determine the genetic code that effects the hyper growth and viability 
of probiotics and also to use HPLC and ion chromatography determined the amino acids 
produced during the fermentation process. 
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Appendix A 
Methods to measure carbohydrates in shiitake mushroom 
 
Instrument  
-Spectrophotometer 
-5 ml pipette 
Chemical used: 
-Phenol 5% w/v, dissolve 5g of analytical reagents grade phenol in water and dilute to 1 liter 
Sulphuric acid (98%) analytical-reagents grade. 
Glucose standards solution. (i) Stock solution 1.0 mg/ml. dissolve 1.0 g in water and dilute to 
volume 1000 ml volumetric flask (ii) working standards solution 0-0.05 mg/ml. 
Transfer 0-5 ml of stock solution separately to 100 ml volumetric flask and dilute to volume with 
water.  
Instruction to follow method: 
Extract about 0.25 g of ground dried shiitake mushroom with soxhelt apparatus for two hour (i.e 
until essentially fat free). 
Transfer the extracted shiitake mushroom to an evaporating glass dish and dry to constant 
weight, then heat the sample for 3 hours with 100 ml of water and 10 ml of hydrochloric acid in 
a 250 ml flask, provided a reflux condenser. Cool, filter and transfer the filtered to a 250 ml 
volumetric flask and diluted to mark. Pipette 10 ml of this solution to volumetric flask to make 
100 ml of solution. Pipette 1 ml of the solution and standard solution separately to test tubes. To 
each tube add 1 ml of 5% phenol in water and then add 5 ml of concentrated H2SO4 rapidly for 
10-20 mint water bath 25-30 ⁰C before readings at 490 nm are taken. 
- Blank are prepared substituting distilled water for sugar solution. Plot a curve from the 
reading of the standard and calculate the amount of CHO in sample expressed as weight 
% of glucose n sample.  
- %CHO =     conc. (mg/ml)x 250 ml               x 100 ml  x100%   = conc.x250   (as 
gulocose) 
-                    Sample wt (g) x1000(mg/ml) x 10 ml                          sample wt 
 
 
Source: Chang and Quinnio (1982), p. 87 
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Appendix B 
 
Calculating the amount of carbohydrates in shiitake mushroom 
 
 
 
ID 
 
absorbance 
     
    
conc. aborb. ppm slope 
0.50  
 
-0.014 
 
0.50  -0.014 0.26  2.24E+02 
1.00  
 
-0.011 
 
1.00  -0.011 0.93  
 2.00  
 
-0.002 
 
2.00  -0.002 2.95  intercept 
5.00  
 
0.004 
 
5.00  0.004 4.29  3.39  
10.00  
 
0.03 
 
10.00  0.03 10.11  
 20.00  
 
0.074 
 
20.00  0.074 19.96  correl. 
       
0.99739 
    
PPM 
   sample 
 
0.031 
 
10.34  
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Appendix C 
 
Shiitake mushroom preparation for metal analysis 
 
 
Synopsis: 
a. Microwave Digestion to solubilize all metal. 
b. ICP/OES analysis to identify and quantities all metal 
 
a. Microwave Digestion (MW); 
 
1. Weigh approx. 0.1000 gm and record weight 
2. Add to digestion tube. 
3. Add 7 ml conc. HNO3 and 3 ml conc. HCL to the digestion tube. 
4. Place in MW and program the oven to heat to 200ºC in 15 minutes and then hold 
oven at 200ºC in 15 minutes. 
5. After  MW digestion is over let samples cool to below 60ºC  
6. Transfer the sample to 50 ml graduate cylinder and build to 50 ml mark with DI 
water and hold for ICP/OES analysis. 
7. A good digestion will be crystal clear. 
 
b. ICP/OES analysis: 
 
1. prepare standard analyte (s) for all metal of interest  
2. prepare the concentration curve ( for element analysis)to cover the low and high 
ends of the expected values ( range 0.05ppm-500.0 ppm. 
3. Follow the ICP/OES manufacture‟s operation manual to complete the metal 
analysis. 
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Appendix D 
 
Shiitake mushroom metal analysis 
 
 
      
         
         metal      mg in digested sample   mg/kg in sample 
         Lithium 
  
0.001 
   
10.4 
 iron 
  
0.003 
   
33.6 
 Zink 
  
0.003 
   
34.3 
 boron 
  
0.006 
   
72.9 
 Copper 
  
0.007 
   
100 
 Silicone 
  
0.011 
   
134 
 Calcium 
  
0.012 
   
167 
 Sodium 
  
0.051 
   
717 
 magnesium 
 
0.107 
   
1,423 
 Phosphorus 
 
0.496 
   
6,607 
 Sulfur 
  
0.538 
   
7,178 
 potassium 
 
2.114 
   
28,165 
 Aluminum 
 
0.004 
   
53 
  
